Travere Therapeutics (TVTX) 10-K/A 9 Jul 15 2013 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2013	Jun. 30, 2015	Jun. 30, 2013
Document And Entity Information
Entity Registrant Name	Retrophin, Inc.
Entity Central Index Key	1,438,533
Trading Symbol	rtrx
Entity's Reporting Status Current	Yes
Entity a Voluntary Filer	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity a Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		35,072,757
Entity Public Float			$ 41,994,436
Document Type	10-K/A
Document Period End Date	Dec. 31, 2013
Amendment Flag	false
Document Fiscal Year Focus	2,013
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)		Dec. 31, 2013		Dec. 31, 2012
Current assets:
Cash		$ 5,997,307	[1]	$ 11,388
Marketable securities		132,994	[1]
Prepaid expenses and other current assets		1,370,943	[1]	$ 21,830
Total current assets		7,501,244	[1]	33,218
Property and equipment, net		$ 127,427	[1]	23,790
Due from affiliate				$ 137,547
Security deposits		$ 244,058	[1]
Restricted cash		40,000	[1]
Indefinite lived intangible assets	[1]	10,560,355
Other Amortizable intangible assets, net		2,025,795	[1]	$ 2,196,710
Total assets		$ 20,498,879	[1]	2,391,265
Current liabilities:
Technology license liability				$ 1,300,000
Deferred technology purchase liability, current portion		$ 1,634,630	[1]
Accounts payable		3,553,567	[1]	$ 1,023,320
Accrued expenses		4,881,434	[1]	$ 2,467,796
Securities sold, not yet purchased		$ 1,457,901	[1]
Note payable - related party				$ 884,764
Investors' deposits				100,000
Due to related parties				$ 23,200
Derivative financial instruments, warrants		$ 25,037,346
Total current liabilities		36,564,878	[1]	$ 5,799,080
Deferred technology purchase liability		1,000,000	[1]
Deferred income tax liability, net		2,600,899	[1]
Total liabilities		$ 40,165,777	[1]	$ 5,799,080
Commitments and contingencies
Stockholders' Deficit:
Preferred stock Series A $0.001 par value; 20,000,000 shares authorized; 0 issued and outstanding as of December 31, 2013 and 2012, respectively
Common stock $0.0001 par value; 100,000,000 shares authorized; 18,546,363 and 8,952,905 issued and 18,415,573 and 8,952,905 outstanding, respectively		$ 1,855	[1]	$ 895
Additional paid-in capital		49,635,502	[1]	$ 30,203,402
Treasury stock, at cost, 130,790		(957,272)	[1]
Deficit accumulated during the development stage		(68,236,996)	[1]	$ (33,612,112)
Accumulated other comprehensive loss		(109,987)	[1]
Total stockholders' deficit		(19,666,898)	[1]	$ (3,407,815)
Total liabilities and stockholders' deficit		$ 20,498,879	[1]	$ 2,391,265
[1]	(As Restated)

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares		Dec. 31, 2013		Dec. 31, 2012
Statement of Financial Position [Abstract]
Preferred stock Series A, par value (in dollars per share)		$ 0.001	[1]	$ 0.001
Preferred stock Series A, shares authorized		20,000,000	[1]	20,000,000
Preferred stock Series A, stock issued		0	[1]	0
Preferred stock Series A, shares outstanding		0	[1]	0
Common stock, par value (in dollars per share)		$ 0.0001	[1]	$ 0.0001
Common stock, shares authorized		100,000,000	[1]	100,000,000
Common stock, shares issued		18,546,363	[1]	8,952,905
Common stock, shares outstanding		18,415,573	[1]	8,952,905
Treasury stock, shares	[1]	130,790
[1]	(As Restated)

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)		12 Months Ended			34 Months Ended
		Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
Operating expenses:
Selling, general and administrative - inclusive of share base compensation $2,650,845, $22,410,222, and $27,040,366		$ 17,689,439	[1]	$ 29,594,515	$ 50,315,639	[1]
Research and development - inclusive of share based compensation $259,076, $0, and $259,076		7,084,009	[1]	662,502	7,978,522	[1]
Total operating expenses		24,773,448	[1]	30,257,017	58,294,161	[1]
Operating loss		(24,773,448)	[1]	(30,257,017)	(58,294,161)	[1]
Other income (expenses):
Interest expense, net		(46,344)	[1]	(84,087)	(130,356)	[1]
Registration payment obligation income	[1]	360,000			360,000
Registration payment obligation expense	[1]	(360,000)			(360,000)
Realized gain on sale of marketable securities, net	[1]	374,482			374,482
Change in fair value of derivative financial instruments - warrants	[1]	(10,099,926)			(10,099,926)
Loss on transactions denominated in foreign currencies		(3,873)	[1]	(2,752)	(11,260)	[1]
Total other expense, net		(9,775,661)	[1]	(86,839)	(9,867,060)	[1]
Loss before provision for income taxes		(34,549,109)	[1]	$ (30,343,856)	(68,161,221)	[1]
Provision for income taxes		(75,775)	[1]		(75,775)	[1]
Net loss		$ (34,624,884)	[1]	$ (30,343,856)	(68,236,996)	[1]
Net loss per common share, basic and diluted (in dollars per share)		$ (2.44)	[1]	$ (8.29)
Weighted average common shares outstanding, basic and diluted (in shares)		14,205,264	[1]	3,662,114
Comprehensive Loss:
Net loss		$ (34,624,884)	[1]	$ (30,343,856)	(68,236,996)	[1]
Unrealized loss on marketable securities	[1]	(109,987)			(109,987)
Comprehensive Loss		$ (34,734,871)	[1]	$ (30,343,856)	$ (68,346,983)	[1]
[1]	(As Restated)

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parentheticals) - USD ($)	12 Months Ended			34 Months Ended
	Dec. 31, 2013	[1]	Dec. 31, 2012	Dec. 31, 2013	[1]
Statement of Comprehensive Income [Abstract]
Compensation and related costs - Share based compensation	$ 2,650,845		$ 22,410,222	$ 27,040,366
Research and development - share based compensation	$ 259,076		$ 0	$ 259,076
[1]	(As Restated)

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)		Common Stock		Common Stock in Treasury		Additional paid in capital		Receivables due from Stockholder	Accumulated other comprehensive loss		Accumulated Deficit		Total
Balance at Mar. 11, 2011
Balance (in shares) at Mar. 11, 2011
Issuance of common shares		$ 161				$ 24,839		$ (25,000)
Issuance of common shares (in shares)		1,608,300
Issuance of common shares to founders in connection with the initial capital contribution		$ 5				95							$ 100
Issuance of common shares to founders in connection with the initial capital contribution (in shares)		50,000
Incentive shares granted - employees		$ 176				(176)
Incentive shares granted - employees (in shares)		1,758,300
Share based compensation - employees						1,724,967							$ 1,724,967
Share based compensation - non employees						254,332							$ 254,332
Incentive shares granted- non employees		$ 38				(38)
Incentive shares granted- non employees (in shares)		381,000
Incentive shares forfeited - employees		$ (5)				5
Incentive shares forfeited - employees (in shares)		(45,835)
Issuance of shares in connection with March 2011 private placement, net of fees of $66,061		$ 25				658,914							$ 658,939
Issuance of shares in connection with March 2011 private placement, net of fees of $66,061 (in shares)		253,750
Issuance of Series A preferred in connection with March 2011 private placement, net of fees of $1,367, recapitalization to common stock		$ 4				$ 103,629							103,633
Issuance of Series A preferred in connection with March 2011 private placement, net of fees of $1,367, recapitalization to common stock (in shares)		36,750
Loan made to stockholder								$ (10,000)					(10,000)
Net loss											$ (3,268,256)		(3,268,256)
Balance at Dec. 31, 2011		$ 404				$ 2,766,567		(35,000)			(3,268,256)		$ (536,285)
Balance (in shares) at Dec. 31, 2011		4,042,265
Prior Issuance of Series A preferred in connection with January 2012 private place, net of fees of $61,677, exchanged to common stock		$ 33				1,806,644							$ 1,806,677
Prior Issuance of Series A preferred in connection with January 2012 private place, net of fees of $61,677, exchanged to common stock (in shares)		326,963
Prior Issuance of Series A preferred in connection with May 2012 private place, net of fees of $12,275, exchanged to common stock		$ 47				1,668,979							1,669,026
Prior Issuance of Series A preferred in connection with May 2012 private place, net of fees of $12,275, exchanged to common stock (in shares)		470,764
Shares transferred to consultants by founder for services		$ 0				4,400,000							4,400,000
Shares transferred to consultants by founder for services (in shares)		0
Shares transferred to employees by founder for services		$ 0				1,375,000							1,375,000
Shares transferred to employees by founder for services (in shares)		0
Shares issued in accordance with technology license agreement		$ 62				1,549,938							1,550,000
Shares issued in accordance with technology license agreement (in shares)		620,000
Shares outstanding at time of reverse merger date December 12, 2012		$ 259				1,142							1,401
Shares outstanding at time of reverse merger date December 12, 2012 (in shares)		2,585,583
Incentive shares granted - employees		$ 86				(86)
Incentive shares granted - employees (in shares)		866,180
Share based compensation - employees						14,638,850							14,638,850
Share based compensation - non employees						1,997,372							1,997,372
Incentive shares granted- non employees		$ 9				(9)
Incentive shares granted- non employees (in shares)		87,503
Incentive shares forfeited - employees		$ (5)				5
Incentive shares forfeited - employees (in shares)		(46,353)
Receivable due from stockholder charged to compensation								407,900					407,900
Loan made to stockholder								$ (372,900)					(372,900)
Net loss											(30,343,856)		(30,343,856)
Balance at Dec. 31, 2012		$ 895				30,203,402					(33,612,112)		(3,407,815)
Balance (in shares) at Dec. 31, 2012		8,952,905
Balance at Dec. 31, 2012		$ 895				30,203,402					(33,612,112)		(3,407,815)
Balance (in shares) at Dec. 31, 2012		8,952,905
Balance at Dec. 31, 2012		$ 895				30,203,402					(33,612,112)		(3,407,815)
Balance (in shares) at Dec. 31, 2012		8,952,905
Balance at Dec. 31, 2012		$ 895				30,203,402					(33,612,112)		(3,407,815)
Balance (in shares) at Dec. 31, 2012		8,952,905
Incentive shares granted - employees		$ 14				(14)
Incentive shares granted - employees (in shares)		135,000
Share based compensation - employees						1,424,528							1,424,528
Share based compensation - non employees		$ 18				1,485,357							1,485,375
Share based compensation - non employees (in shares)		177,500
Consultants Settlement		$ 18				1,179,750							1,179,768
Consultants settlement (in shares)		181,500
Incentive shares forfeited - employees		$ (2)				2
Incentive shares forfeited - employees (in shares)		(20,833)
Incentive shares forfeited - non employees		$ (4)				4
Incentive shares forfeited - non employees (in shares)		(37,500)
Issuance of common stock in connection with January 2013 private placement at $3.00 per share, net of fees of $0		$ 27				816,637							816,664
Issuance of common stock in connection with January 2013 private placement at $3.00 per share, net of fees of $0 (in shares)		272,221
Issuance of common stock in connection with February 2013 private placement at $3.00 per share, net of fees of $928,986 and registration payment obligation of $360,000		$ 305				2,441,124							2,441,429
Issuance of common stock in connection with February 2013 private placement at $3.00 per share, net of fees of $928,986 and registration payment obligation of $360,000 (in shares)		3,045,929
Issuance of common stock in connection with August 2013 private placement at $4.50 per share, net of fees of $2,780,563 and payment made to February investors for inducement to participate in August financing of $2,238,681		$ 553				10,670,020							10,670,573
Issuance of common stock in connection with August 2013 private placement at $4.50 per share, net of fees of $2,780,563 and payment made to February investors for inducement to participate in August financing of $2,238,681 (in shares)		5,531,401
Issuance of common stock in connection with payment made to February investors for inducement to participate in August financing, 271,222 shares at $4.50 per share and 20,685 shares at $5.00 per share		$ 29				1,323,894							1,323,923
Issuance of common stock in connection with payment made to February investors for inducement to participate in August financing, 271,222 shares at $4.50 per share and 20,685 shares at $5.00 per share (in shares)		291,907
Treasury stock				$ (957,272)									$ (957,272)
Treasury stock (in shares)				(130,790)									130,790
Shares issued on behalf of related party		$ 1				80,799							$ 80,800
Shares issued on behalf of related party (in shares)		11,000
Adjustment to existing shareholder		$ 1				9,999							10,000
Adjustment to existing shareholder (in shares)		5,333
Unrealized loss on marketable securities									$ (109,987)				(109,987)	[1]
Net loss											(34,624,884)		(34,624,884)	[1]
Balance at Dec. 31, 2013		$ 1,855	[1]	$ (957,272)	[1]	$ 49,635,502	[1]		$ (109,987)	[1]	$ (68,236,996)	[1]	$ (19,666,898)	[1]
Balance (in shares) at Dec. 31, 2013	[1]	18,546,363		(130,790)
[1]	(As Restated)

CONSOLIDATED STATEMENT OF CHAN7

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - USD ($)	1 Months Ended
	Aug. 31, 2013	Feb. 28, 2013	Jan. 31, 2013	May. 30, 2012	Jan. 31, 2012	Mar. 31, 2011
Statement of Stockholders' Equity [Abstract]
Common shares issuance fees	$ 2,780,563	$ 928,986	$ 0			$ 66,061
Preferred shares issuance fees				$ 12,275	$ 61,677	$ 1,367
Issuance of common stock, per share amount (in dollars per share)	$ 4.50	$ 3	$ 3
Registration payment obligation expense		$ 360,000
Payment made to investors for inducement to participate in financing	$ 2,238,681
Shares issued to investors for inducement to participate in financing (in shares)	271,222
Issuance of common stock to investors, per share amount (in dollars per share)	$ 4.50
Shares issued to investors for inducement to participate in financing	20,685
Issuance of common stock to investors, per share amount (in dollars per share)	$ 5

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)		12 Months Ended			34 Months Ended
		Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss		$ (34,624,884)	[1]	$ (30,343,856)	$ (68,236,996)	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		215,993	[1]	124,885	341,233	[1]
Realized gain on marketable securities	[1]	$ (374,482)			(374,482)
Compensation in lieu of stockholder receivable				407,900	407,900	[1]
Provision for income taxes	[1]	$ 75,775			75,775
Share based compensation - employees		1,424,528	[1]	16,012,850	19,162,345	[1]
Share based compensation - non-employees		4,020,143	[1]	6,397,372	10,671,847	[1]
Shares issued on behalf of related party	[1]	80,800			80,800
Registration payment obligation expense	[1]	360,000			360,000
Reversal of registration payment obligation liability	[1]	$ (360,000)			(360,000)
Share based payment - Technology license contingent fee				1,550,000	1,550,000	[1]
Change in estimated fair value of liability classified warrants	[1]	$ 10,099,926			10,099,926
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(1,349,113)	[1]	(14,830)	(1,370,943)	[1]
Technology license fees				150,000	150,000	[1]
Accounts payable and accrued expenses		2,842,146	[1]	2,978,940	6,330,941	[1]
Net cash used in operating activities		(17,589,168)	[1]	(2,736,739)	(21,111,654)	[1]
Cash Flows From Investing Activities:
Purchase of fixed assets		(117,033)	[1]	(24,774)	(144,679)	[1]
Purchase of indefinite lived intangible assets	[1]	(5,400,601)			(5,400,601)
Purchase of amortizable intangible asset		(31,682)	[1]	(1,168,093)	(1,199,775)	[1]
Security deposits	[1]	(106,511)			(106,511)
Repayment of technology license liability	[1]	(1,300,000)			(1,300,000)
Proceeds from the sale of marketable securities	[1]	4,385,425			4,385,425
Purchase of marketable securities	[1]	(4,124,482)			(4,124,482)
Proceeds from securities sold, not yet purchased	[1]	4,193,719			4,193,719
Cover securities sold, not yet purchased	[1]	(2,865,260)			(2,865,260)
Increase in restricted cash	[1]	(40,000)			(40,000)
Cash received in merger transaction				3,721	3,721	[1]
Payments made on behalf of affiliate				(137,547)	(137,547)	[1]
Loans made to shareholder				(372,900)	(382,900)	[1]
Net cash used in investing activities		(5,406,425)	[1]	(1,699,593)	(7,118,890)	[1]
Cash Flows From Financing Activities:
Proceeds from related parties				10,500	56,500	[1]
Repayment of net amounts due to related parties		(13,200)	[1]	(33,300)	(46,500)	[1]
Proceeds from note payable - related party				930,000	930,000	[1]
Repayment of note payable - related party		(884,764)	[1]	(45,236)	(930,000)	[1]
Investors' deposits		(100,000)	[1]	100,000
Proceeds received from issuance of common stock, net		30,936,748	[1]	3,475,703	35,175,123	[1]
Purchase of treasury stock, at cost	[1]	(957,272)			(957,272)
Net cash provided by financing activities		28,981,512	[1]	4,437,667	34,227,851	[1]
Net increase in cash		5,985,919	[1]	1,335	5,997,307	[1]
Cash, beginning of year		11,388	[1]	10,053
Cash, end of year	[1]	5,997,307		11,388	5,997,307
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest		28,263	[1]	14,764	43,027	[1]
Non-cash investing and financing activities:
Unrealized gain on marketable securities	[1]	3,292			3,292
Unrealized loss on securities sold, not yet purchased	[1]	(113,279)			(113,279)
Forfeiture of subscription receivable Technology license liability	[1]				25,000
Reclassification of due from related parties				500
Technology License liability				$ 1,300,000
Adjustment to existing shareholders	[1]	10,000			10,000
Purchase of Kyalin in exchange for future consideration	[1]	2,634,630			2,634,630
Affiliate receivable applied to security deposit	[1]	137,547			137,547
Share based payment made to February investors for inducement to participate in August financing	[1]	1,323,923			1,323,923
Offering expense liability	[1]	746,739			746,739
Increase in basis of indefinite lived intangible assets acquired from Kyalin due to accrual of deferred tax liability	[1]	$ 2,525,124			$ 2,525,124
[1]	(As Restated)

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2013
Description Of Business [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1. DESCRIPTION OF BUSINESS Organization and Description of Business Retrophin, Inc. (the “Company”) was incorporated as Desert Gateway, Inc. (“Desert Gateway”) in the State of Oklahoma on February 8, 2008. Desert Gateway was originally a wholly-owned subsidiary of American Merchant Data Services, Inc. (“American Merchant”). In a 2008 reorganization of American Merchant, each share of outstanding common stock of American Merchant was converted into one share of Desert Gateway, while all of American Merchant’s operating assets, liabilities and tax attributes (including accumulated losses and net operating losses) carried forward to another subsidiary of American Merchant in a downstream merger with such other subsidiary. Accordingly, American Merchant was not considered a predecessor company of the Desert Gateway for accounting or legal purposes. Following the 2008 reorganization, Desert Gateway re-domiciled to Delaware. Since inception and until Desert Gateway’s merger with Retrophin, Inc., a private company (“Former Retrophin”) in December 2012 (as described below), Desert Gateway had no existing operations, and its sole purpose was to locate and consummate a merger or acquisition with a private entity. Former Retrophin, Inc. was originally organized as a Delaware limited liability company, named Retrophin, LLC, on March 11, 2011 (“Inception”). On September 20, 2012, Retrophin filed a Certificate of Conversion to change its legal form of organization from a limited liability company to a corporation in the State of Delaware. This conversion (as more fully described in Note 15) into a corporation, which preceded the Merger on December 12, 2012, resulted in no change of ownership and was therefore considered a recapitalization of the LLC’s equity. On September 13, 2012, Former Retrophin formed a new entity, Retrophin Pharmaceutical, Inc., a Delaware corporation and wholly-owned subsidiary of Retrophin, Inc. On December 12, 2012, Desert Gateway completed the transactions contemplated under the Agreement and Plan of Merger, dated as of December 12, 2012 (the “Merger Agreement”), by and among Desert Gateway, Desert Gateway Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Desert Gateway, and Former Retrophin, our predecessor, in which Former Retrophin became a wholly-owned subsidiary and the principal operating subsidiary of the Company. The transactions contemplated by the Merger Agreement are collectively referred to herein as the “2012 Merger”. The Merger became effective on December 12, 2012, upon the filing of a certificate of merger with the Secretary of State of the State of Delaware. Accordingly, the Merger resulted in a change in control of Desert Gateway. Desert Gateway’s net assets amounted to $1,401 at the time of the merger, including $3,721 of cash and $2,320 of trade liabilities. The merger was accounted for as a reverse merger and recapitalization of Former Retrophin into Desert Gateway, whereby Desert Gateway is the legal acquirer and Former Retrophin is the legal acquiree and the accounting acquirer in this transaction. Upon the consummation of the Merger all of the issued and outstanding Class A Preferred shares of Former Retrophin were exchanged into the Company’s common shares at the rate of 1 to 7 (each Class A Preferred stockholder received 7 shares of the Company’s common stock) and all of the issued and outstanding share of common stock of Former Retrophin were exchanged for shares of the Company’s common stock on exchange ratio of 1 to 5 (each Common stockholder of Former Retrophin received 5 shares of the Company’s common stock). The consolidated financial statements give retroactive effect to these changes as if the merger occurred at the inception of the Company. On February 14, 2013, the Company changed its name to “Retrophin, Inc.” through a short-form merger pursuant to Section 253 of the Delaware General Corporation Law, with its then wholly owned subsidiary, and our predecessor, Retrophin, with the Company continuing as the surviving corporation following the merger. On April 1, 2013, the Company changed its fiscal year end from the last day of February to December 31 in order to conform its reporting cycle to that of Former Retrophin. Retrophin, is an emerging biotechnology company dedicated to developing drugs for rare and life-threatening diseases. Retrophin’s primary business objective is to develop and commercialize therapies for orphan diseases. The Company is considered to be a development stage company and, as such, the Company’s financial statements are prepared in accordance with Accounting Standards Codification (“ASC”) 915, “Development Stage Entities” (“ASC 915”). The Company is subject to all of the risks and uncertainties associated with development stage companies.

RESTATEMENTS OF PREVIOUSLY ISSU

RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	12 Months Ended
	Dec. 31, 2013
Restatements Of Previously Issued Consolidated Finacial Statements [Abstract]
RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2. RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (1) In September 2014, the Company’s board of directors requested that the Company’s outside legal counsel conduct an investigation (the “Investigation”) into the circumstances surrounding the negotiation and execution by the former Chief Executive Officer of the Company, Martin Shkreli, of certain consulting and settlement agreements entered into by the Company. The Investigation also covered additional agreements and other matters involving Mr. Shkreli during his tenure as the Chief Executive Officer of the Company. In January 2015, the Company’s board of directors appointed an Oversight Committee of the board of directors (the “Oversight Committee”), consisting of Gary Lyons and Jeffrey Meckler, each of whom was not a member of the Company’s board of directors during the period of time covered by the Investigation. The Company’s board of directors delegated to the Oversight Committee the independent and plenary authority to oversee and direct the Investigation and make findings and decisions related to the Investigation. Following the investigation, the Oversight Committee concluded the following: · In September 2013 and December 2013, the Company entered into two consulting agreements and releases with individuals or entities that had been investors in investment funds previously managed by Mr. Shkreli (the “MSMB Entities”), or that otherwise had financial dealings with Mr. Shkreli. The agreements provided for the issuance of a total of 346,500 shares of common stock of the Company, and a total of $200,000 in cash payments by the Company. The Oversight Committee concluded that the Company should not continue to treat these agreements as consulting agreements because their predominant purpose appears to have been to settle and release claims against the MSMB Entities or Mr. Shkreli personally, and not to provide meaningful and sustained consulting services to the Company. The Oversight Committee also determined that the Company paid approximately $165,000 of legal fees, and $135,000 of other professional fees on behalf of the MSMB Entities, which were charged to operations during the year ended December 31, 2013. The Related Party Transactions note has been updated to include this disclosure. The Oversight Committee concluded that certain of the transactions described above were consummated without specific approval of the Company’s board of directors or without the Company’s board of directors knowing all of the relevant facts. Quantitative Impact on Previously Issued Interim and Annual Financial Statements The following table sets forth the effects (in thousands) of the matters identified by the Oversight Committee on affected items within the Company’s previously reported Consolidated Balance Sheets for the periods ended September 30, 2013 and December 31, 2013. September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Non-derivative liabilities $ 4,935 $ 7,090 $ 13,774 $ 15,129 Derivative financial instruments, warrants 23,853 23,853 25,037 25,037 Total Liabilities 28,788 30,943 38,811 40,166 Additional paid in capital 47,498 46,220 50,189 49,636 Deficit accumulated during the development stage (54,768 ) (55,645 ) (67,436 ) (68,237 ) Stockholder’s deficit $ (7,423 ) $ (9,578 ) $ (18,312 ) $ (19,667 ) The following table sets forth the effects (in thousands) of the matters identified by the Oversight Committee on affected items within the Company’s previously reported Consolidated Statement of Operations for the three months ended September 30, 2013 and December 31, 2013 had the adjustments been made in the corresponding quarters: September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Selling, General and Administrative $ 3,755 $ 4,631 $ 6,747 $ 6,672 Operating loss (5,155 ) (6,031 ) (11,717 ) (11,642 ) Net loss (11,135 ) (12,011 ) (12,668 ) (12,592 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.78 ) $ (0.73 ) $ (0.73 ) The following table sets forth the effects (in thousands) of the matters identified by the Oversight Committee on affected items within our previously reported Consolidated Statement of Operations for the nine and twelve months ended September 30, 2013, and December 31, 2013 respectively, had the adjustments been made in the corresponding quarters. September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Selling, General and Administrative $ 10,141 $ 11,017 $ 16,888 $ 17,689 Operating loss (12,255 ) (13,131 ) (23,972 ) (24,773 ) Net loss (21,156 ) (22,033 ) (33,824 ) (34,625 ) Net loss per share, basic and diluted $ (1.65 ) $ (1.72 ) $ (2.38 ) $ (2.44 ) *For matters identified during the fourth quarter of 2013 described in (2) below. (2) As previously discussed in the Form 10-K for the year ended 2013, in the fourth quarter of 2013, the Company discovered that certain warrants issued to a placement agent in connection with our February 14, 2013 Private Placement Offering (“February Private Placement”), were not recorded and certain expenses were misstated in our condensed consolidated financial statements for the first, second, and third quarters of 2013. The misstated expenses include costs related to the February Private Placement, certain accruals, consulting fees, and changes in the fair value of the unrecorded warrants, which required liability classification. Quantitative Impact on Previously Issued Interim Financial Statements The following table (in thousands) sets forth the effects of the restatement on affected items within our previously reported Consolidated Balance Sheets for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters. March 31, 2013 June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised As Reported As Revised Non-derivative liabilities $ 1,575 $ 1,460 $ 4,229 $ 4,229 $ 4,935 $ 4,935 Derivative financial instruments, warrants 6,957 8,349 6,901 8,283 22,234 23,853 Total Liabilities 8,532 9,809 11,130 12,512 27,169 28,788 Additional paid in capital 34,772 33,620 34,945 33,793 48,650 47,498 Deficit accumulated during the development stage (38,355 ) (38,480 ) (43,404 ) (43,634 ) (54,301 ) (54,768 ) Stockholder’s deficit $ (3,582 ) $ (4,859 ) $ (8,457 ) $ (9,839 ) $ (5,804 ) $ (7,423 ) The following table (in thousands) sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the three months ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters. March 31, 2013 June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised As Reported As Revised Selling, General and Administrative $ 2,141 $ 1,777 $ 4,495 $ 4,610 $ 3,755 $ 3,755 Operating loss (2,250 ) (1,885 ) (5,100 ) (4,215 ) (5,155 ) (5,155 ) Non-operating loss (2,492 ) (2,982 ) 51 61 (5,743 ) (5,980 ) Net loss (4,742 ) (4,867 ) (5,049 ) (5,154 ) (10,898 ) (11,135 ) Net loss per common share, basic and diluted $ (0.44 ) $ (0.46 ) $ (0.41 ) $ (0.42 ) $ (0.71 ) $ (0.72 ) The following table (in thousands) sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the six months ended June 30, 2013 and the nine months ended September 30, 2013, respectively, had the adjustments been made in the corresponding quarters. June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised Selling, General and Administrative $ 6,636 $ 6,387 $ 10,391 $ 10,141 Operating loss (7,350 ) (7,100 ) (12,505 ) (12,255 ) Non-operating loss (2,441 ) (2,921 ) (8,184 ) (8,901 ) Net Loss (9,791 ) (10,021 ) (20,689 ) (21,156 ) Net loss per common share, basic and diluted $ (0.85 ) $ (0.87 ) $ (1.62 ) $ (1.65 ) The cumulative effect of all errors discussed in (1) and (2) on our results of operations for the period from March 11, 2011 through December 30, 2013 for purposes of development stage reporting is that our cumulative loss in the amount of $67.4 million, as reported, is now $68.2 million, as restated.

LIQUIDITY AND FINANCIAL CONDITI

LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT'S PLANS	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT'S PLANS	NOTE 3. LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT’S PLANS The Company incurred a net loss of approximately $68.2 million, including stock-based compensation of $27.3 million for the period from March 11, 2011 (inception) to December 31, 2013. At December 31, 2013, the Company had a cash balance of approximately $6.0 million and a working capital deficiency of approximately $29.1 million; however, the working capital deficit includes a derivative liability of approximately $25.0 million for warrants issued in financing transactions. The Company’s accumulated deficit amounted to approximately $68.2 million at December 31, 2013. The Company has principally financed its operations from inception using proceeds from sales of its equity securities in a series of private placement transactions (see Note 15). On January 9, 2014, the Company raised gross proceeds of approximately $40 million. The Company to date has no revenues, significantly limited capital resources and is subject to all of the risks and uncertainties that are typical of a development stage enterprise. Significant uncertainties include, among others, whether it will be able to raise the capital it needs to finance its planned operations and whether such operations, if launched, will enable the Company to become a profitable enterprise. On August 14, 2013, the Company and the investors who participated in the private placement transaction that the Company completed on February 14, 2013, entered into the first amendment to the registration rights agreement (the “Amended Registration Rights Agreement”) associated with that transaction. The Amended Registration Rights Agreement provides, among other things, for (i) a waiver of any and all liquidated damages that the Company incurred for its inability to cause the a registration statement to be declared effective within certain contractually defined time-frames stipulated in the original agreement; (ii) a commitment on the part of the investors in the February private placement to participate in a private placement transaction that the Company completed on August 15, 2013, and (iii) a covenant on the part of the Company to proceed with the sale of shares that were issued under the August 15, 2013 private placement transaction. In exchange, the Company paid an aggregate fee to these investors of $2,495,256 consisting of (i) 73,710 shares of the Company’s common stock with an aggregate fair value of $331,695 (based on the selling price of $4.50 per share in the August financing transaction); (ii) cash in the amount of $1,835,000; and (iii) warrants to purchase 98,756 shares of common stock with a fair value of $328,561. The investors were also given the option to purchase shares of the Company’s common stock at $4.50 as a use of the cash portion of the payment arrangement. Accordingly, $946,196 of the cash portion of the fee was settled in cash and the remainder was settled by the issuance of 197,512, shares. Additionally, the Company paid $103,425 to an investor to whom the Company sold shares in a private placement transaction in January 2013 and who participated in the August 2013 private placement transaction. This payment was settled entirely by the issuance of 20,685 shares of the Company’s common stock at a value of $5.00 per share (see Note 15). In the second quarter of 2013, the Company, its Chief Executive Officer and a related party became parties to a series of agreements to settle up to $2,284,511 of liabilities, which Company management believes are the primary obligation of the related party. The Company paid $593,111 of these settlements in the second quarter on behalf of the related party and had outstanding liabilities of $1,691,400 as of September 30, 2013, which the Company paid as of the date of this filing. Concurrent with the execution and payment of such settlement agreements, the Company entered into indemnification agreements and received promissory notes from the related party whereby the related party agreed to pay the Company the principal amount of $2,284,511 plus interest at an annualized rate of 5% as reimbursement of payments that the Company made to settle a portion of the agreements. The Chief Executive Officer also agreed to deliver or cause to be delivered 47,128 shares of common stock to one of the counter parties as a separate component of one of these agreements. Accordingly, the Company does not believe it is required to record a liability for the shared-based component of this specific agreement during the third quarter ended September 30, 2013. There is uncertainty as to whether the related party will have sufficient liquidity to repay the Company or fund the indemnification agreements should it become necessary (see Note 13). In addition, on August 29, 2013, the Company entered into and paid an additional settlement agreement for $300,000. Effective October 1, 2013, the Company signed a Sponsored Research Agreement (“SRA”) with St. Jude Children’s Research Hospital (“St. Jude”). Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of the agreement, the SRA shall be in full force and effect for a period of two (2) years and shall expire on October 1, 2015. The term may be extended by written agreement between the parties. The Company and St. Jude will collaborate on research focused on the study of PKAN disease and other infectious diseases (see Note 14). On December 12, 2013, the Company entered into an agreement with Novartis Pharma AG and Novartis AG pursuant to which Novartis and Novartis AG agreed to grant the Company an exclusive, perpetual, and royalty-bearing license for the manufacture, development and commercialization of Syntocinon and related intranasal products in the United States. Under the license, Novartis and Novartis AG are obligated to transfer to the Company certain information that is necessary for or related to the development or commercialization of Syntocinon. The Company is responsible for conducting research and preclinical, clinical and other development of Syntocinon at its expense, and must use commercially reasonably efforts to develop Syntocinon in the United States. As consideration for the license, the Company paid to Novartis and Novartis AG a $5 million upfront fee and is required to pay annual maintenance fees of $3 million after each anniversary until there has been regulatory approval, up to $34 million in developmental milestones for the first indication and up to $32 million in developmental milestones for the second indication. Should the Company commercialize the Product, it will be obligated to pay Novartis and Novartis AG a 10%-20% royalty on net sales of such products (see Note 8). On December 12, 2013, the Company entered into an agreement “Weg License Agreement,” with Stuart Weg, MD, pursuant to which Dr. Weg agreed to grant the Company an exclusive worldwide license for the manufacture, development and distribution of products to be developed for the treatment of central nervous system disorders. As consideration for the license, the Company paid Dr. Weg $1,000,000, as well as certain maintenance and sublicensing fees. The Company is also obligated to pay Dr. Weg certain royalties on sales of Food and Drug Administration (the “FDA”) approved products. On December 12, 2013, the Company entered into an agreement with The Regents of the University of California, on behalf of its San Diego Campus (“UCSD”), pursuant to which UCSD will undertake research projects related to a study on oxytocin. As consideration for the research program, the Company is obligated to pay an aggregate of approximately $1.54 million in fees to UCSD on a specified timeline, of which $0 has been paid as of the date hereof. As of December 31, 2013, the Company has accrued $40,082 in relation to the agreement. The Company is obligated to pay $192,500 per quarter through 2015. This agreement will continue until completion of the projects, unless earlier terminated by either party (i) due to a material uncured breach of such agreement by the other party or (ii) for any reason by giving written notice to the other party within 60 days. On December 16, 2013 (the “Effective Date”), the Company announced that it had withdrawn its proposal to acquire all of the issued and outstanding shares of common stock of Transcept Pharmaceuticals, Inc. (“Transcept”). The Company no longer owns any shares of Transcept’s common stock. The Company realized a gain of $235,839 on the sale of Transcept shares for the year ended December 31, 2013. On December 16, 2013, the Company entered into an employment agreement (the “Shkreli Employment Agreement”) with Martin Shkreli, pursuant to which Mr. Shkreli will continue to serve as the Company’s Chief Executive Officer (“CEO”). In accordance with the terms of the Shkreli Employment Agreement, Mr. Shkreli will be paid (i) a base salary in the amount of $300,000 (subject to adjustments at the discretion of the Company’s board of directors after each anniversary of the Effective Date), and (ii) at the sole discretion of the board, an annual bonus award based upon specific goals and performance metrics. On December 23, 2013, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Kyalin Biosciences, Inc., a Delaware corporation (“Kyalin”), pursuant to which the Company acquired all of the issued and outstanding shares of capital stock (the “Shares”) from the Kyalin Sellers (“Sellers”). In consideration for the Shares, the Company agreed to pay to the Sellers (i) $1 million of cash consideration at specified dates; and (ii) up to $4 million of the Company’s common stock, par value $0.0001 per share at certain dates and subject to the achievement of certain milestones. Under certain limited circumstances, the Company would be required to pay to the Sellers, in the place of such shares of common stock, an amount of cash equal to one-half (1/2) of the value of the shares of common stock issuable in accordance with the Stock Purchase Agreement (see Note 8.) On March 26, 2014, the Company acquired 100% of the outstanding membership interests of Manchester Pharmaceuticals, LLC (“Manchester” or “acquiree”), a privately-held specialty pharmaceutical company that focuses on treatments for rare diseases. The acquisition of Manchester expands the Company’s ability to address the special needs of patients with ultra-rare diseases. Under the terms of the agreement, the Company paid $29.5 million upon closing, of which $3.2 million was paid by Retrophin Therapeutics International LLC, a newly formed indirect wholly owned subsidiary, for rights of product sales outside of the United States. The Company entered into a promissory note with Manchester principals for $33 million to be paid in three equal installments of $11 million within three, six, and nine months after closing. Additional contingent payments will be made based on product sales. The Company expects to raise additional funds through a public equity offering, a private equity offering, and/or debt financing to satisfy its short term obligations. The financial statements of the acquiree are not practicable to prepare at the time of filing due to the acquiree being privately held and not maintaining financial statements in accordance with U.S. GAAP. The initial accounting for the business combination is not yet complete and the Company is still performing procedures to determine the appropriate accounting. As such, the Company is unable to make the following disclosures, (i) pro forma data, (ii) purchase price allocation, (iii) expenses of the acquisition, and (iv) revenue and earnings of the acquiree since the acquisition date. Management believes the Company’s ability to continue its operations depends on its ability to raise capital. The Company’s future depends on the costs, timing, and outcome of regulatory reviews of its product candidates and the costs of commercialization activities, including product marketing, sales and distribution. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. During the year ended December 31, 2013, the Company raised approximately $30.9 million in certain private placement transactions and raised an additional $40 million in gross proceeds through a public offering in January 2014. The Company expects to continue to finance its cash needs through additional public offerings, private equity offerings and debt financings, corporate collaboration and licensing arrangements and grants from patient advocacy groups, foundations and government agencies. Although management believes that the Company has access to capital resources, there are no commitments for financing in place at this time, nor can management provide any assurance that such financing will be available on commercially acceptable terms, if at all.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying consolidated financial statements follows: Principles of Consolidation The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiary in conformity with United States of America generally accepted accounting principles (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. Cash For purposes of the statement of cash flows, the Company considers cash instruments with maturities of less than three months when purchased to be cash equivalents. There are no cash equivalents as of the balance sheet date. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. Marketable Securities The Company accounts for marketable securities held as “available-for-sale” in accordance with ASC 320, “Investments Debt and Equity Securities” (“ASC 320”). The Company classifies these investments as current assets and carry them at fair value. Unrealized gains and losses are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income. Realized gains or losses on marketable security transactions are reported in earnings and computed using the specific identification of cost basis. Marketable securities are maintained at one financial institution and are governed by the Company’s investment policy as approved by our Board of Directors. Fair values of marketable securities are based on quoted market prices. Valuation of marketable securities are further describe in Note 5. Securities Sold, Not Yet Purchased Securities sold, not yet purchased consist of marketable securities that the Company has sold short. In order to facilitate a short sale, the Company borrows the securities from another party and delivers the securities to the buyer. The Company will be required to "cover" its short sale in the future through the purchase of the security in the market at the prevailing market price and deliver it to the counterparty from which it borrowed. The Company is exposed to a loss to the extent that the security price increases during the time from when the Company borrowed the security to when the Company purchases it in the market to cover the short sale. The Company accounts for securities sold, not yet purchased in accordance with ASC 815 – Derivative and Hedging (“ASC 815”), which states such transactions have two of the three characteristics of a derivative instrument and do not generally involve derivative instruments. Securities sold, not yet purchased are presented on the consolidated balance sheets with gains and losses reported in realized and unrealized gains on marketable securities on the consolidated statement of operations and comprehensive loss. Restricted Cash The Company holds restricted cash as a rent guarantee on an operating lease through September 2016. Employee Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, “Stock Compensation” (“ASC 718”). ASC 718 addresses all forms of share- based payment (“SBP”) awards including shares issued under employee stock purchase plans and stock incentive shares. Under ASC 718 awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest and will result in a charge to operations. Non-Employee Stock-Based Compensation The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, “Share Based Payments to Non-Employees” (“ASC 505”), and ASC 718 which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest. Non-employee stock-based compensation charges are being amortized over their respective contractual vesting periods. Use of Estimates In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets and estimating the fair value of long-lived assets to assets whether impairment charges may apply. Research and Development Costs The Company develops new products through research and development and the licensing and acquisition of third-party businesses and technologies. Research and development costs are charged to operations as incurred and consist primarily of internal and external expenses related to conducting clinical trials, pre-clinical studies, regulatory activities, consulting, contract research and development, and compensation. For the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized $7,084,009, $662,502 $7,978,522, respectively, of research and development costs. Income Taxes The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. Since the Company was incorporated on March 11, 2011, all of its years of operations will be subject to examination. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material changes to its consolidated financial position. The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest as of or during the period from March 11, 2011 (inception) through December 31, 2013. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. Prior to conversion into a corporation on September 20, 2012, as a limited liability company, the Company was treated as a partnership for federal and state income tax purposes. Accordingly, no provision has been made for federal and state income taxes in the accompanying financial statements for any periods preceding September 20, 2012, since all items of income or loss are required to be reported on the income tax returns of the members, who are responsible for any taxes thereon. Profits and losses are allocated based upon capital in accordance with the permissible methods under Internal Revenue Code Section 704. Further, the Company incurred losses since inception through September 20, 2012, that would have resulted in the recognition of deferred tax assets that would have been fully reserved had the Company been subject to income taxes. The Company is subject to the New York City Unincorporated Business Tax through September 19, 2012. Subsequent to the Company’s conversion to a corporation from a limited liability company on September 20, 2012, the Company reports and pays taxes based on its income or loss. Foreign Currency Translation and Remeasurement The Company accounts for foreign currency translation and remeasurement in accordance with ASC 830, “Foreign Currency Matters” (“ASC 830”). Under ASC 830, currency assets and liabilities are translated into the reporting currency, US Dollars, using period end rates of exchange and the related translation adjustments are recorded as a separate component of accumulated other comprehensive income. Functional statements of operations amounts expressed in functional currencies are translated using average exchange rates for the respective periods. Remeasurement adjustments and gains or losses resulting from foreign currency transactions are recorded as foreign exchange gains or losses in the consolidated statements of operations. Patents The Company capitalized external cost, such as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company expense cost associated with maintaining and defending patents subsequent to their issuance in the period incurred. The Company amortizes patent cost once issued on a straight-line basis over the estimate useful lives of the patents. The Company assesses the carrying amounts of its patents for potential impairment when events or changes in circumstances indicate that the carrying amounts of our patents may not be recoverable. As of December 31, 2013 and 2012, patents costs of $49,775 and $18,093, respectively, are included in the accompanying consolidated balance sheets. Long-Lived Assets The Company accounts for long-lived assets in accordance with ASC 360, “Long-lived assets, other than goodwill, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or any other significant adverse change that would indicate that the carrying amount of an asset or group of assets may not be recoverable. Application of alternative assumptions, such as changes in estimate of future cash flows, could produce significantly different results. Because of the significance of the judgments and estimation processes, it is likely that materially different amounts could be recorded if we used different assumptions or if the underlying circumstances were to change. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and estimated fair value. Basic and diluted Net Loss Per Share Basic and diluted net loss per share has been computed by dividing net loss by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded since their inclusion would be anti-dilutive. An aggregate of 4,462,426 and 0 warrants were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because their inclusion would have an anti-dilutive effect for the periods presented. An aggregate of 172,667 and 0 stock options were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because they would have an anti-dilutive effect for the periods presented. An aggregate of 168,643 and 267,768 incentive shares were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because they were contingent shares subject to recall. On January 9, 2014, the Company completed a public offering of 4.7 million shares of common stock at a price of $8.50 per share (see Note 18). Subsequent to year end, an aggregate of 798,391 warrants were exercised for a total of $3,830,316 in cash received by the Company (see Note 18). Derivative Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company calculates the fair value of the financial instruments using the Binomial Lattice options pricing model at inception and on each subsequent valuation date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period (see Note 6 and Note 7). Joint and Several Liability Arrangements The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has a) contractually agreed to pay, and b) any additional amounts that the Company expects to pay on behalf of its co-obligors. Financial Instruments and Fair Value The Company accounts for financial instruments in accordance with ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC Topic 820”). ASC Topic 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described below: Level 1 Level 2 Level 3 In estimating the fair value of the Company’s marketable securities available-for-sale and securities sold, not yet purchased, the Company used quoted prices in active markets (see Note 5 and Note 7). In estimating the fair value of the Company’s derivative liabilities, the Company used the Binomial Lattice pricing model (see Note 6 and Note 7). Financial assets with carrying values approximating fair value include cash as well as marketable securities, deposits on license agreements, prepaid expenses and other current assets. Financial liabilities with carrying values approximating fair value include accounts payable and accrued expenses. Treasury Stock Treasury stock is recorded at cost. Issuance of treasury stock is accounted for on a first-in, first-out basis. Differences between the cost of treasury stock and the re- issuance proceeds are charged to additional paid-in capital. Registration Payment Arrangements The Company accounts for registration payment arrangements in accordance with ASC 825-20, “Registration Payment Arrangements” (“ASC 825-20”) ASC 825- 20 addresses an issuer’s accounting for registration payment arrangements. This pronouncement specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument, should be separately recognized and accounted for as a contingency in accordance with ASC 450-20, “Loss Contingencies” (“ASC 450”). Reclassifications Certain prior year financial statement balances have been reclassified to conform to the current year presentation. These reclassifications had no effect on the recorded net loss. The Company reclassified research and development expenses and selling, general, and administrative expenses. Subsequent Events The Company follows the provisions of ASC Topic 855-10, “Subsequent Events” (“ASC 855-10”) relating to subsequent events. This guidance establishes principles and requirements for subsequent events. This guidance defines the period after the balance sheet date during which events or transactions that may occur would be required to be disclosed in a company’s financial statements. The Company has evaluated subsequent events up to the date of issuance of this report. Recently Issued Accounting Pronouncements In February 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-04 “Obligations Resulting from Joint and Several Liability Arrangements for Which the Amount at the Reporting Date is Fixed” (“ASU 2013-04”). The guidance in this update is effective for fiscal years beginning after December 15, 2013 with early adoption permitted. The guidance in this update requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount the entity has a) contractually agreed to pay, and b) any additional amounts that the entity expects to pay on behalf of its co-obligors. The Company early adopted this guidance in the second quarter of 2013 (Note 3 and Note 13). The FASB has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company has not yet determined the effect of the adoption of this standard and it is not expected to have a material impact on the Company’s consolidated financial position and results of operations. Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a significant effect on the accompanying consolidated financial statements.

MARKETABLE SECURITIES AND SECUR

MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]
MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED	NOTE 5. MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED The Company measures marketable securities and securities sold, not yet purchased on a recurring basis. Generally, the types of securities the Company invests in are traded on a market such as the NASDAQ Global Market, which the Company considers to be Level 1 inputs. Marketable securities and securities sold, not yet purchased at December 31, 2013 consisted of the following: Cost Unrealized Gains Unrealized Estimated Fair Marketable securities available-for-sale: $ 129,702 $ 3,292 $ - $ 132,994 Securities sold, not yet purchased $ 1,344,622 $ 13,256 $ 126,535 $ 1,457,901 For the year ended December 31, 2012, marketable securities and securities sold, not yet purchased were $0.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2013
Investments, All Other Investments [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 6. DERIVATIVE FINANCIAL INSTRUMENTS The Company accounts for derivative financial instruments in accordance with ASC Topic 815-40, “Derivative and Hedging – Contracts in Entity’s Own Equity” (“ASC Topic 815-40”), instruments which do not have fixed settlement provisions are deemed to be derivative instruments. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, the warrants issued in connection with the sale of the common stock during the year ended December 31, 2013 that do not have fixed settlement provisions, are not indexed to the Company’s own stock. The fair value of the warrants are classified as liability instruments due to a non-standard anti-dilution provision that provides for a reduction to the exercise price of the warrants if the Company issues additional equity or equity linked instruments in the future at an effective price per share less than the exercise price then in effect. The warrants are re-measured at each balance sheet date based on estimated fair value. Changes in estimated fair value are recorded as non-cash valuation adjustments within other income (expense) in the Company’s accompanying consolidated statements of operations. The Company recorded a loss on a change in the estimated fair value of warrants of $10,099,926 during the year ended December 31, 2013 The Company calculated the fair value of the warrants using the Binomial Lattice pricing model. The assumptions used at the date of issuance and at December 31, 2013 are noted in the following table: As of Date of issuance Date of issuance Date of issuance December 31, 2013 Fair market price of common stock $ 3.75 $ 4.50 $ 4.50 $ 7.00 Contractual term 5 years 5 years 5 years 4.12 – 4.62 years Risk-free interest rate 0.86 % 1.48 % 1.48 % 1.39% Expected volatility 101 % 106 % 106 % 93% – 97% Expected volatility is based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected terms of the warrants, as the Company does not have a long trading history to estimate the volatility of its own common stock. The warrants have a transferability provision. Based on guidance provided in SEC Staff Accounting Bulletin No. 107 (“SAB 107”) for options issued with such a provision, the Company used the full contractual term as the initial expected term of the warrants. The risk free interest rate is based on the U.S. Treasury security rates for the remaining term of the warrants at the measurement date. The following tables illustrates the Company’s derivative warrant issuances and balances outstanding as of, and during the years ended December 31, 2013 and 2012: Weighted Average Warrants Exercise Price Fair Value Outstanding at December 31, 2011 - $ - $ - Issued - - - Canceled - - - Exercised - - - Outstanding at December 31, 2012 - $ - $ - Issued 4,782,249 5.04 3.13 Canceled - - - Exercised - - - Outstanding at December 31, 2013 4,782,249 $ 5.04 $ 5.23 The following information applies to derivative warrants outstanding at December 31, 2013: Weighted Average Exercise Price Number of Warrants Life (years) Number Exercisable $ 3.60 1,917,792 4.12 1,917,792 $ 6.00 2,864,457 4.62 2,864,457 The total intrinsic value of derivative warrants outstanding and exercisable as of December 31, 2013 is $9,384,950. The Company’s closing stock price was $7 on December 31, 2013.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 7. FAIR VALUE MEASUREMENTS The following table presents the Company’s asset and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2013: As of December 31, 2013 Fair Value Hierarchy at December 31, 2013 Quoted prices in Significant other Significant Total carrying and active markets observable inputs unobservable estimated fair value (Level 1) (Level 2) inputs (Level 3) Asset: Marketable securities, available-for-sale $ 132,994 $ 132,994 $ - $ - Liabilities: Derivative liability related to warrants $ 25,037,346 $ - $ - $ 25,037,346 Securities sold, not yet purchased $ 1,457,901 $ 1,457,901 $ - $ - Settlement agreement $ 1,155,000 $ 1,155,000 $ - $ - The following table sets forth a summary of changes in the estimated fair value of the Company’s Level 3 liability for the year ended December 31, 2013: Fair Value Balance at January 1, 2013 $ - Issuance of common stock warrants: February 14, 2013 5,407,372 August 14, 2013 328,561 August 15, 2013 9,201,487 Total value upon issuance 14,937,420 Change in fair value of common stock warrant liability 10,099,926 Balance at December 31, 2013 $ 25,037,346 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC Topic 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8. INTANGIBLE ASSETS Indefinite lived intangible assets The Company purchased, and currently owns (i) an exclusive, perpetual, and royalty-bearing license exclusive for the manufacture, development and commercialization of a product in the United States (ii) technology related to an intranasal formulation compound. The intellectual property underlying the license and formula is held in perpetuity. These intangible assets are measured initially at cost not subject to amortization and are tested for impairment annually or in interim reporting periods if events or changes in circumstances indicate that the carrying amounts of these intangible asset might not be recoverable. FASB ASC 740-10-55 (“ASC 740”) addresses the accounting treatment when an asset is acquired outside of a business combination, and the tax basis of that asset differs from the amount paid. As a result of this guidance, the Company has stepped-up the basis of its intangible assets and has recorded a deferred tax liability in the same amount, to account for the basis difference resulting from the Kyalin acquisition. Indefinite lived intangible assets as of December 31, 2013 consist of the following: Syntocinon License $ 5,000,000 Carbetocin Assets 5,560,355 Total $ 10,560,355 2013 Activity Syntocinon License Agreement On December 12, 2013 (the “Effective Date”), the Company entered into an agreement with Novartis Pharma AG and Novartis AG pursuant to which Novartis and Novartis AG agreed to grant the Company an exclusive, perpetual, and royalty-bearing license for the manufacture, development and commercialization of Syntocinon (the “Product”) and related intranasal products in the United States. Under the license, Novartis and Novartis AG are obligated to transfer to the Company certain information that is necessary for or related to the development or commercialization of Syntocinon. The Company is responsible for conducting research and preclinical, clinical trials and other development of Syntocinon at its expense, and must use commercially reasonably efforts to develop Syntocinon in the United States. As consideration for the license, the Company paid to Novartis Pharma AG and Novartis AG a $5 million upfront fee and is required to make substantial payments at certain dates and upon the achievement of certain milestones as follows: (i) annual payments of $3,000,000 after each anniversary of the Effective Date until there has been Regulatory Approval of the Product for use in an autism or schizophrenia indication from the U.S. Food and Drug Administration, (ii) a milestone payment of $2,000,000 after the first patient is enrolled in a clinical trial for any indication not set forth in the New Drug Application (“NDA”) filed by Novartis on January 19, 1960 for the following indications: initial milk let-down, milk retention, incipient mastitis, impaired milk let-down, (the “Initial NDA registration”), (iii) a milestone payment of $2,000,000 after the first patient is enrolled in a registration study in the first indication for the Product for any indication not set forth in the Initial NDA, (iv) a milestone payment of $2,000,000 after the first patient is enrolled in a registration study in the second indication for the Product for any indication not set forth in the Initial NDA, (v) a milestone payment of $5,000,000 after the receipt of positive results from a registration study in the first indication for the Product for any indication not set forth in the Initial NDA (vi) a milestone payment of $5,000,000 after receipt of positive results from a registration study in the second indication for the Product for any indication not set forth in the Initial NDA, (vii) a milestone payment of $10,000,000 after filing an NDA for the first indication for any indication not set for the in the Initial NDA, (viii) a milestone payment of $10,000,000 after filing an NDA for the second indication for any indication not set for the in the Initial NDA, (ix) a milestone payment of $15,000,000 after Regulatory Approval of the Product in the first indication from FDA for any indication not set forth in the Initial NDA, (x) a milestone payment of $15,000,000 after Regulatory Approval of the Product in the second indication from FDA for any indication not set forth in the Initial NDA. Should the Company commercialize the Product, it will be obligated to pay Novartis and Novartis AG a 10%-20% royalty on net sales of such products. The Company capitalized the $5,000,000 upfront fee as an indefinite lived intangible asset. The Company will test for impairment when events and circumstances indicate that the assets might be impaired. As of December 31, 2013, the Company has accrued the annual maintenance fee in the amount of $150,000. Kyalin - Carbetocin Technology Purchase On December 23, 2013 (the “Closing Date”), the Company entered into a Stock Purchase Agreement with Kyalin to acquire substantially all of Kyalin’s assets which include patents, patent applications, contracts and data related to the intranasal formulation of the compound Carbetocin (collectively, the “Carbetocin Assets”) Carbetocin, similar to Oxytocin, has potential utility for the treatment of milk let-down in post pregnant women, inducing contractions during labor, postpartum hemorrhage, as well as for autism and schizophrenia. The Company determined to treat the Stock Purchase Agreement as an asset acquisition in accordance with ASC 805, “Business Combinations” (“ASC 805”). In accordance with ASC 805, the Company is required to determine whether the transaction meets the definition of a business combination, which requires that the assets acquired and liabilities assumed constitute a business. The form in which the transaction takes place typically will not affect the determination of whether the acquisition is a business. A business is identified by evaluating whether there is sufficient continuity of operations so that disclosure of prior financial information is material to an understanding of future operations. Kyalin has had significantly limited activity since its formation on October 4, 2011. The Company agreed to pay to the Sellers $3,000,000 of fixed minimum payments consisting of: (i) $500,000 of cash at closing, (ii) $500,000 of cash on the first anniversary of the Closing Date, (iii) $1,000,000 of the Company’s common stock, par value $0.0001 per share common stock on the first anniversary of the Closing Date, (iv) $1,000,000 of the Company’s common stock, par value $0.0001 per share common stock on the second anniversary of the Closing Date, and up to $2,000,000 of additional consideration thereafter, subject to the attainment of following milestones, (v) $800,000 of the Company’s common stock, par value $0.0001 per share common stock after completion of the first Phase II study of a compound that meets its primary endpoint and would enable the Company to subsequently move the respective compound into a Phase III Study, (vi) $800,000 of the Company’s common stock, par value $0.0001 per share common stock after completion of the first Phase III Study of a compound that meets its primary endpoint such that the safety and efficacy data from such Phase III Study may be included in an NDA for a drug with the FDA, (vii) $400,000 of the Company’s common stock, par value $0.0001 per share common stock after receipt of FDA approval of an NDA for a drug. On the closing date of the acquisition, the Company paid $365,370 and recorded a liability of $2,634,630. As of December 31, 2013, the Company has recorded a liability of $634,630 for the cash and $2,000,000 for value of shares payable at certain future dates in accordance with the stock purchase agreement. Share payments shall be issued based on the greater of (a) the average price per share quoted 30 trading days immediately preceding the date such shares first become issuable or (b) $7.0938 per share. The Company has recorded a deferred purchase asset liability of $2,634,630. In accordance with ASC 740, the Company has stepped-up the basis of its intangible assets in the amount of $2,525,124 and has recorded a deferred tax liability in the same amount, to account for the basis difference resulting from the Kyalin acquisition (see Note 17). Amortizable intangible assets 2012 Activity Ligand License Agreement On February 16, 2012 the Company entered into an agreement pursuant to which a biotechnology company (‘the Sublicensor’) with license rights to certain drug technologies agreed to grant the Company a worldwide sublicense for the development, manufacture and commercialization of Sparsentan (DARA). The license agreement also enables the Company to sell the licensed technology as a research product or sublicense the technology to other third parties as potential sources of revenue. Under the license agreement, Sublicensor is obligated to transfer to the Company certain information, records, regulatory filings, materials and inventory controlled by Sublicensor and relating to or useful for developing Sparsentan. The Company must use commercially reasonable efforts to develop and commercialize Sparsentan in specified major market countries and other countries in which the Company believes it is commercially reasonable to develop and commercialize such products. The agreement shall continue until neither party has any obligations under the agreement to make payments to the other party. In accordance with the agreement as amended most recently as of January 7, 2013, the Company was obligated to make two non-refundable payments totaling $2,550,000, the first payment of $1,150,000 was made upon execution and the second payment of $1,400,000 was made in February 2013, and includes a $250,000 fee payable to the sublicensee in exchange for extending the due date of this payment from October 1, 2012 to February 2013. As of December 31, 2013, the Company has recognized $2,300,000 for the cost of the License Agreement which is presented in the accompanying consolidated balance sheet as an intangible asset that is being amortized on a straight-line basis over the term of the License Agreement which expires on September 30, 2023. The $250,000 extension fee was expensed in February 2013. In addition, the Company issued 620,000 common shares to Ligand valued at $1,550,000 following the completion of the Merger transaction as required under the terms of the agreement. The fair value of these shares was expensed to operations in December 2012. Amortization expense on intangibles was $202,597, $121,383, and $323,890 for the year ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, respectively, and was recorded in the statement of operations as Research and Development expense. In addition, the Company is obligated to make series of milestone payments upon the achievement of each development milestone event set forth in the sublicense agreement which could amount to an aggregate of up to $106.9 million. Per the sublicense agreement, starting from the first commercial sale of any licensed product (as defined in the agreement), the Company is obligated to pay the Sublicensor royalty payments equal to 15% of annual worldwide net sales of licensed product up to $300,000. For worldwide net sales of licensed product exceeding $300,000, a royalty percentage of 17% is applied. Royalties are payable on a quarterly basis, and are payable on a product-by-product and country-by country basis on the net sales of licensed products. Royalties terms will be in effect until the later of (i) ten years after the first commercial sale of any licensed product in such country or (ii) the expiration of any patent rights licensed under the license agreement (iii) the expiration of all periods of market exclusivity. Currently, the last to expire issued patent covered by such arrangement expires in September 2023; however, the Company expects such date may be extended by patent-term extensions. The sublicense agreement contains other customary clauses and terms as are common in similar agreements in the industry. Amortizable intangible assets as of December 31, 2013 and 2012 consist of the following: December 31, 2013 Gross Carrying Accumulated Net Book Value Lingand License $ 2,300,000 $ (323,980 ) $ 1,976,020 Patent Costs* 49,775 - 49,775 Total $ 2,349,775 $ (323,980 ) $ 2,025,795 December 31, 2012 Gross Carrying Accumulated Net Book Value Lingand License $ 2,300,000 $ (121,383 ) $ 2,178,617 Patent Costs* 18,093 - 18,093 Total $ 2,318,093 $ (121,383 ) $ 2,196,710 *Patent costs will be amortized when a patent is procured and a life is assigned to the asset As of December 31, 2013, amortization expense for the next five years is expected to be as follows: 2014 $ 202,597 2015 202,597 2016 202,597 2017 202,597 2018 202,597 thereafter 1,012,810 Total $ 2,025,795 As of December 31, 2013 the remaining weighed average period of amortization is 9.54 years.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 9. ACCRUED EXPENSES Accrued expenses consist of the following at December 31, 2013 and 2012: December 31, 2013 December 31, 2012 Compensation related costs $ 1,144,983 $ 1,022,716 Research and development 1,035,875 679,800 Business development 300,000 - License fee 150,000 - Accounting and legal fees 75,000 563,380 Finder’s fee - 100,000 Other - 11,250 Interest - 90,650 Other operating expenses 1,428,837 - Offering costs 746,739 - Total $ 4,881,434 $ 2,467,796

SELLING, GENERAL, AND ADMINISTR

SELLING, GENERAL, AND ADMINISTRATIVE	12 Months Ended
	Dec. 31, 2013
Selling General And Administrative
SELLING, GENERAL, AND ADMINISTRATIVE	NOTE 10. SELLING, GENERAL, AND ADMINISTRATIVE Selling, general, and administrative expenses consist of the following at December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013: For the period from March 11, 2011 (inception) through December 31, December 31, December 31, 2013 2012 2013 Professional fees (inclusive of share base compensation $1,485,393, $6,397,372, and $8,137,097) $ 5,600,455 $ 9,035,702 $ 15,249,423 Other 7,564,241 725,263 8,386,902 Compensation and related costs (inclusive of share base compensation 4,274,743 18,133,550 24,729,314 Technology license contingent fees 250,000 1,700,000 1,950,000 Total selling, general, and administrative expenses $ 17,689,439 $ 29,594,515 $ 50,315,639

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	12 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT	NOTE 11. RESEARCH AND DEVELOPMENT Research and development expenses consist of the following at December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013: For the period from March 11, 2011 through December 31, December 31, December 31, 2013 2012 2013 External service provider costs: Sparsentan $ 2,443,273 $ 297,833 $ 2,619,723 RE-024 1,548,957 124,635 1,673,592 Weg license in process R&D (Note 14) 1,000,000 - 1,000,000 Syntocinon 250,540 - 250,540 RE-034 230,279 - 230,279 General 159,080 240,034 493,569 Other product candidates 117,771 - 376,710 Total external service provider costs: 5,749,900 662,502 6,644,413 Internal personnel costs (inclusive of share base compensation $259,076, $0, and $259,076): 1,334,109 - 1,334,109 Total research and development $ 7,084,009 $ 662,502 $ 7,978,522

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 12. NOTES PAYABLE Note Payable - related party On February 1, 2012, the Company entered into a secured promissory note with a related party in the amount of $900,000, with an interest rate of 12% per annum, compounded monthly. The note plus accrued unpaid interest was originally due i) on or prior to December 31, 2012 or ii) upon consummation of a Sale of the Company to acquire (a) a majority of the outstanding equity securities, or (b) all or substantially all of the Company's assets on a consolidated basis. On March 5, 2012, an aggregate payment of $25,000 was made by the Company, of which $9,764 was applied to accrued interest and the remaining balance of $15,236 was applied to the principal balance. The remaining principal balance of this note amounts to $884,764 as of December 31, 2012, was repaid during the quarter ended March 31, 2013. Note Payable - employee On September 30 2012, the Company received an advance of $30,000 from a related party in the form of a promissory note, with an interest rate of 15% per annum, compounded monthly. On December 3, 2012, the Company repaid $30,000 plus any unpaid interest. Total interest expense recognized for the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013 were aggregated to $41,563, $105,917, and $147,480, respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13. RELATED PARTY TRANSACTIONS In August 2012, the Company paid a security deposit on behalf of an affiliate of $137,547 in connection with a building lease entered into by such affiliate. The Company assumed the lease from its affiliate in April 2013, whereby the security deposit was assigned to the Company. During the year 2012, the Company paid an aggregate amount of $563,380 in legal fees on behalf of the same affiliate. The affiliate is currently in the process of dissolving and the Company does not expect to collect the amount outstanding. As a result, the Company has written-off $563,380 to bad debt expense in 2012. Such charge is included in selling general and administrative expense in the statement of operations. In the second quarter of 2013, the Company, its Chief Executive Officer and a related party, which is a former investor in the Company that was previously managed by the Company’s Chief Executive Officer, became party to a series of agreements to settle up to $2,284,511 of liabilities, which Company management believes are the primary obligation of the related party. The Company and the related party have entered into indemnification agreements whereby the related party has agreed to defend and hold the Company harmless against all such obligations and amounts, whether paid or unpaid, arising from these agreements. Notwithstanding the indemnification, the Company recorded a $2,284,511 charge to operations for the year ended December 31, 2013 for the (a) $2,203,711 of cash consideration, and (b) 11,000 shares of common stock valued at $80,800 of non-cash consideration. The $2,284,511 is entirely paid as of the date of this filing. In addition, the Chief Executive Officer also agreed to provide one of the counter parties with 47,128 shares of his common stock in the Company as a separate component of one of these settlement agreements. Accordingly, the Company does not believe it is required to record a liability for the shared-based component of this specific agreement. There is uncertainty as to whether the related party will have sufficient liquidity to repay the Company or fund the indemnification agreements should it become necessary. Concurrent with the execution of such settlement agreements, the Company and the related party entered into promissory notes whereby the related party agreed to pay the Company the principal amount of $2,284,511 plus interest at an annualized rate of 5% as reimbursement of payments that the Company made to settle a portion of the agreements. The Company applied the accounting guidance provided in ASU 2013-04. The guidance in this update is effective for fiscal years beginning after December 15, 2013 with early adoption permitted. The guidance in this update requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount that the entity has a) contractually agreed to pay, and b) any additional amounts that the entity expects to pay on behalf of its co-obligors. The Company has recorded the full amount of the settlements as a charge to its operations due to uncertainty as to whether the related party will have sufficient liquidity to repay the Company or fund the indemnification agreements should it become necessary. Any amounts that the Company may recover under the note due from the related party or under the terms of the indemnification agreement, if in fact any amounts are recovered at all, would be characterized as a capital contribution at the date such payments are received. On August 15, 2013, the Company closed a private placement and sold 5,531,401 shares of the Company’s common stock, at a purchase price of $4.50 per share, or $24,891,303 in the aggregate, and warrants to purchase up to an aggregate of 2,765,701 shares of common stock with an exercise price of $6.00 per share underlying each warrant. Members of the Company’s management purchased an aggregate of 10,522 shares of common stock and warrants to purchase up to an aggregate of 5,261 shares of common stock in such private placement. The Warrants are deemed to be derivative instruments due to a ratchet provision that adjusts the exercise price if the Company issues additional equity instruments in the future at an effective price per share less than the exercise price then in effect. The issuance of the shares of common stock in such private placement was not registered under the Securities Act as such issuance was exempt from registration under Section 4(2) of the Securities Act and Regulation D promulgated thereunder. In September 2013 and December 2013, the Company entered into two separate settlement agreements and releases with individuals or entities that were investors in MSMB Entities, or that otherwise had financial dealings with Mr. Shkreli. The agreements provided for the issuance of a total of 346,500 shares of common stock of the Company, and a total of $200,000 in cash payments by the Company. Under the first agreement the Company entered into on September 20, 2013, the Company agreed to issue 331,500 shares of common stock follows (i) 131,500 shares of common stock issued upon execution of the agreement, (ii) 50,000 shares of common stock issued on September 30, 2013, (iii) 50,000 shares of common stock issued on December 31, 2013, (iv) 50,000 shares of common stock issued on March 31, 2014, and (v) 50,000 shares issued on June 30, 2014. Under the second agreement entered into on December 31, 2013, the Company agreed to issue 15,000 shares of common stock issued and paid upon the date of execution. During the term of the agreement, the Company was required to pay the consultant $50,000 per month. The Company recorded a $2,708,375 charge to operations for the cash and aggregate issuance date fair value of the shares issued/issuable under these agreements and subsequently marked the remaining share base payment liability to current fair value by recording a credit to operations of $173,625. The Company also paid approximately $165,000 of legal fees and $135,000 of other professional fees on behalf of a related party during the year ended December 31, 2013 that were charged to operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14. COMMITMENTS AND CONTINGENCIES Leases and Sublease In October 2012, the Company entered into a sublease with a company (“Sublessor”) affiliated by common ownership for 4,216 square foot of office space and its principal offices. The sublease agreement required the Company to pay 50% of the rent and related escalations and for the Company to pay for 50% of the utilities incurred by the Sublessor. The Company assumed the building lease from such affiliate in April 2013 for office space at its principal offices in New York, New York and is responsible for rent of approximately $275,000 annually plus rent escalations through August 2016 (see Note 3). On October 1, 2013, the Company entered into building lease for approximately 4,232 square foot of office space located in Cambridge, Massachusetts under which we are responsible for rent of approximately $216,000 annually plus rent escalations, common area maintenance, insurance, and real estate taxes through September 2016. On October 8, 2013, the Company entered into an amended lease agreement for an approximately 4,000 square foot of additional office space at its principal offices in New York, New York and is responsible for additional rent of approximately $225,000 annually plus rent escalations through August 2016. On December 1, 2013, the Company entered into a lease for approximately 2,500 square feet of office space located in Carlsbad, CA that expires in February, 2017. The Company is responsible for approximately $70,500 of annual base rent plus rent escalations, common area maintenance, insurance, and real estate taxes. Consulting Agreements On August 15, 2011, the Company entered into an agreement with a consultant to serve as a senior advisor of strategy. The agreement’s initial term is for one year and automatically renews on an annual basis. Pursuant to this agreement the compensation to the consultant is comprised of (a) a fee of $37,500 per calendar quarter, payable commencing September 30, 2011, and (b) 25,000 shares of the Company common stock with an estimated fair value of $100,000, which vests over twelve (12) quarters so long as the agreement remains in effect. For the years ended December 31, 2013 and 2012, for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized professional fees related to this agreement in the amounts of approximately $153,000, $150,000, and $378,500, respectively, of which amounts comprised of fee payable of $0, $155,000 and $0 at December 31, 2013 and 2012 and for the period from March 11, 2011 (inception) through December 31, 2013, respectively. On November 1, 2011, the Company granted to the same above consultant an additional 120,000 shares of common stock with an estimate fair value of $480,000, which vest in over twelve (12) calendar quarters commencing December 31, 2011. For the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized professional fees related to this share based compensation of $195,000, $210,000, and $445,000, respectively. On October 26, 2013 and December 1, 2013, the Company amended the above consulting agreements to issue the consultant 200,000 additional shares of the Company common stock to the consultant that payable as follows: (i) 100,000 shares on December 31, 2013, (ii) 50,000 shares on March 30, 2014, (iii) 50,000 shares on June 30, 2014. In addition, the consultant amended the fee and shall receive $26,666 per month. The agreement expires on October 25, 2013, and shall automatically extend for one year unless notice of non-extension is given. For the year ended December 31, 2013 and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized professional expense related to this agreement in the amount of approximately $780,000. On August 25, 2011 and November 1, 2011, the Company entered into two agreements with a consultant to serve as chief scientific officer of the Company. The agreements’ initial terms were for one year and automatically renewed on an annual basis. Pursuant to the agreements the compensation to the consultant was comprised of (a) a fee of $50,000 per calendar quarter, and (b) 145,000 incentive shares with an estimated fair value of $580,000, which vested over twelve (12) quarters so long as the agreements remained in effect. For the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized professional expense related to these agreements in amounts of $225,000, $200,000, and 525,000, respectively. These agreements terminated on December 31, 2012. The Company recorded professional expense for the year ended December 31, 2013 for 34,575 vested shares in 2013 that were issued upon execution of the agreements. On February 15, 2013, the Company entered into an agreement with a consultant to provide certain advisory services. The Company granted 12,500 shares of common stock with an estimated value of $52,500. For the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized professional expense related to these agreements in amounts of $52,500, $0, and $52,500, respectively On November 8, 2013, the Company entered into an agreement with a consultant to serve as an advisor to the Company. The Company shall pay the consultant $15,000 per quarter and expires in six months from the date entered into. Sponsored Research Agreements St. Jude On July 1, 2012, the Company entered into a Sponsored Research Agreement with St. Jude Children’s Research Hospital (“St. Jude”) that expired on July 1, 2013. The Company paid sponsor fees totaling $203,169 to the organization to perform the research program stated in the Sponsored Research Agreement. Sponsor fees totaling $203,169 was recognized as professional expense, pro-rata over the one year term of the Sponsored Research Agreement. Total professional expense recorded related to the Sponsored Research Agreement totaled $101,314, $101,855, $203,169 for the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, respectively. Effective October 1, 2013, the Company signed a new Sponsored Research Agreement with St. Jude. The Company is responsible for a total of $780,674 payable in four equal installments on October 19, 2013, March 19, 2014, September 19, 2014, and March 19, 2015. Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of the agreement, the SRA shall be in full force and effect for a period of two (2) years and shall expire on October 1, 2015. The term may be extended by written agreement between the parties. On October 22, 2013, the Company paid $195,169 in accordance with this agreement. For the year ended December 31, 2013, the Company recognized professional expense related to this agreement in the amount of $97,584. SickKids On July 12, 2013, the Company agreed to sponsor a study with The Hospital for Sick Children (“SickKids”). The Company agreed to fund the study by providing a CAD $750,000 (USD $721,470) amount matching Brain Canada’s contribution over a three-year term. The Company paid CAD $250,000 (USD $234,490) on December 3, 2013. The Company is obligated to pay a total of CAD $500,000 (USD $467,425) in CAD $250,000 (USD $233,713) yearly installments through 2015. For the year ended December 31, 2013, the Company recognized professional expense related to this agreement in the amount of $113,327. University of Michigan On October 2, 2013, the Company agreed to provide a charitable contribution to the University of Michigan up to $2,000,000 to be funded in equal quarterly installments over a two-year period commending in October, 2013. On October 2, 2013, the Company paid and expensed $250,000 to the University of Michigan as part of this agreement. The Company reserves the right to cancel this arrangement with no further funding obligation. UCSD On December 11, 2013, the Company entered into an agreement with UC San Diego to provide an unrestricted charitable gift in support of translation psychiatric research at UC San Diego. The total charitable contribution in the amount of $530,000 will be paid in three contribution over a one year period in beginning on January 31, 2014. As of December 31, 2013, the Company has accrued and expensed $530,000 as part of this agreement. On December 12, 2013, the Company entered into an agreement with The Regents of the University of California, on behalf of its San Diego Campus (“UCSD”), pursuant to which UCSD will undertake research projects related to a study on oxytocin over a period of two years. As consideration for the research program, the Company is obligated to pay an aggregate of approximately $1.54 million in fees to UCSD on a specified timeline, of which $0 has been paid as of the date hereof. As of December 31, 2013, the Company has expense and accrued $40,082 in relation to the agreement. The Company is obligation to pay $192,500 per quarter through 2015. This agreement will continue until completion of the projects, unless earlier terminated by either party (i) due to a material uncured breach of such agreement by the other party or (ii) for any reason by giving written notice to the other party within 60 days. License Agreements Weg License Agreement On December 12, 2013, the Company entered into an agreement “Weg License Agreement,” with Stuart Weg, MD, pursuant to which Dr. Weg agreed to grant the Company an exclusive worldwide license for the manufacture, development and distribution of products to be developed for the treatment of central nervous system disorders. As consideration for the license, the Company paid Dr. Weg $1,000,000 upon execution of the agreement. The Company is also obligated to pay Dr. Weg certain royalties on sales of FDA-approved products. Prior to receipt from the FDA of approval for a product for depression indications, the Company agrees to pay Weg an annual license maintenance fee of $1 million. Upon the receipt of FDA approval for any product for depression indication, no further annual maintenance fees are due. The Company agrees to pay a royalty for FDA approved products at a rate of 3% to 8%. The following one-time milestones are due in accordance with the Weg agreement: · $1 million after a patent covering products under the agreement is granted by the U.S. Patent and Trademark Office; · $2.5 million for the first NDA acceptance for depression indication; · $2.5 million after the first FDA approval for products for depression indication; · $2.5 million for the first NDA acceptance of product for an indication not included in the Company’s previously accepted NDA; · $2.5 million for the first FDA approval for products not included in the Company’s previous FDA approval. Other License Agreements During the years ended December 31, 2013 and 2013, the Company entered into license agreements with Novartis and Ligand. The Company is required to pay annual maintenance fees and milestone payments in accordance with these agreements (see Note 3 and 8.) Kyalin Technology Acquisition On December 23, 2013, the Company entered into a Stock Purchase Agreement with Kyalin to acquire substantially all of Kyalin’s assets. The Company is required to pay annual maintenance fees and milestone payments in accordance with the agreement (see Note 3 and 8.) Shkreli Employment agreement On December 16, 2013, the Company entered into a new employment agreement (the “Shkreli Employment Agreement”) with Martin Shkreli, pursuant to which Mr. Shkreli will continue to serve as the Company’s Chief Executive Officer. In accordance with the terms of the Shkreli Employment Agreement, Mr. Shkreli will be paid (i) a base salary in the amount of $300,000 (subject to adjustments at the discretion of the Company’s board of directors after each anniversary of the Effective Date), and (ii) at the sole discretion of the board, an annual bonus award based upon specific goals and performance metrics. Mr. Shkreli will also be awarded options to purchase One Million Eighty Thousand (1,080,000) shares of restricted common stock of the Company, a pro rata portion of which will vest quarterly during the 3 years following the Effective Date. In the event of a change of control of the Company, all of Mr. Shkreli’s unvested options shall immediately vest. The Shkreli Employment Agreement contemplates that Mr. Shkreli’s employment will be for a three-year term and may be automatically extended for successive three-year periods unless (i) Mr. Shkreli gives notice of non-extension to the Company no later than one hundred eighty (180) days prior to the expiration of the Agreement or (ii) Mr. Shkreli is terminated. In the event Mr. Shkreli’s employment is terminated by Mr. Shkreli for good reason (as such term is defined in the Shkreli Employment Agreement), then Mr. Shkreli will be entitled to continue to receive his annual base salary, any unpaid bonus and health insurance coverage on the same terms as made available to the Company’s employees for a period of twelve (12) months following such termination. If Mr. Shkreli’s employment is terminated other than for good reason, Mr. Shkreli will forfeit any unvested stock options that he received and will not be entitled to severance or any additional payments. If Mr. Shkreli’s employment is terminated for cause (as such term is defined in the Shkreli employment Agreement) then Mr. Shkreli will not be entitled to any further payments of any kind, except for payment of base salary plus reimbursement of certain expenses. In the event that Mr. Shkreli is no longer employed by the Company, any options that have not vested prior to the date of termination will be immediately cancelled and not subject to further vesting. Director Compensation On December 6, 2013, the Company’s board of directors established a compensation policy for the Company’s non-employee directors pursuant to which each non-employee director shall receive $100,000 annually, which amount shall be comprised of not more than $25,000 in cash, with the remainder paid in the form of options to purchase shares of the Company’s common stock. Each non-employee director may, at his discretion, determine to receive less than $25,000 annually in the form of cash, in which case such amount will be paid to such director in the form of options to purchase additional shares of the Company’s common stock. In accordance with such policy, in December 2013, the Company issued options to purchase 51,000 shares of common stock to four non-employee directors. Such options vest immediately and are exercisable over a ten year period at an exercise price of $8.70 per share. Withdrawal of Transcept Proposal On September 18, 2013, the Company made a proposal to the board of directors of Transcept Pharmaceuticals, Inc. (“Transcept”) to acquire all of the outstanding shares of Transcept’s common stock for $4.00 per share in cash. The proposal has been rejected by Transcept’s board of directors. The Company invested approximately $3 million and acquired approximately 4.96% of the outstanding common stock of Transcept as part of the proposal process. On December 16, 2013, the Company announced that it had withdrawn its proposal to acquire all of the issued and outstanding shares of common stock of Transcept Pharmaceuticals, Inc. (“Transcept”). The Company no longer owns any shares of Transcept’s common stock. The Company realized a gain of $235,839 on the sale of Transcept shares for the year ended December 31, 2013. Contractual Commitments The following table summarizes our principal contractual commitments, excluding open orders that support normal operations, as of December 31, 2013: Research and Year Ending December 31, Donations Consultants Operating Leases 2014 $ 4,560,092 $ 831,660 $ 777,538 2015 2,950,294 - 811,149 2016 - - 724,292 2017 - - 12,850 2018 - - - 2019 and thereafter - - - Total $ 7,510,386 $ 831,660 $ 2,325,829

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 15. STOCKHOLDERS’ DEFICIT Post-Merger Capitalization with Desert Gateway Common Stock The Company is currently authorized to issue up to 100,000,000 shares of $0.0001 par value common stock. All issued shares of common stock are entitled to vote on a 1 share/1 vote basis. Preferred Stock The Company is currently authorized to issue up to 20,000,000 shares of $0.001 preferred stock, of which 1,000 shares are designated Class "A" Preferred shares, $0.001 par value. Class A Preferred Shares are not entitled to interest, have certain liquidation preferences, special voting rights and other provisions. No Preferred Shares have been issued to date. Issuances Common Stock On March 30, 2011, the Company issued to its founder 1,608,300 shares of Common Stock for a $25,000 capital contribution. On March 31, 2011, the Company issued to a member 50,000 shares of Common Stock for a $100 capital contribution. Private Placement Offering - March 2011 On March 31, 2011, the Company offered for sale, pursuant to a Private Placement Memorandum ("PPM"), up to 500,000 of the Company's Common Stock at $4 per share, for an aggregate offering price of $2,000,000. The Common Stock was entitled to one (1) vote per each unit outstanding. The termination date of this offer was originally May 3, 2011. On June 15, 2011, the Company extended the termination date of the PPM to August 31, 2011. In April, May and June 2011, the Company sold shares of Common Stock in a private placement for $4 per share, yielding aggregate proceeds of $725,000. In addition, the Company incurred aggregate fees of $66,061 in connection with the private placement. These common shares were subsequently exchanged for Series A Preferred shares (subsequently recapitalized into 253,750 shares of common stock). Private Placement Offerings - 2013 In January 2013, the Company sold an aggregate of 272,221 shares of common stock, at a purchase price of $3.00 per share in certain private placement transactions, for an aggregate purchase price of $816,664 in cash. The issuance of such shares of common stock was not registered under the Securities Act as such issuance was exempt from registration under Section 4(2) of the Securities Act and Regulation D promulgated thereunder. On January 4, 2013, the Company entered into an agreement with Roth Capital Partners to act as its exclusive placement agent in connection with the February Private Placement. In connection with the agreement, the Company paid cash fees in the amount of $624,033 and issued warrants to purchase up to an aggregate of 319,823 shares of common stock with an exercise price of $3.60 per such share underlying any warrant. The warrants are deemed to be derivative instruments due to a ratchet provision that adjusts the exercise price if the Company issues additional equity instruments in the future at an effective price per share less than the exercise price then in effect. Upon issuance of the warrants, the Company recorded a liability of $901,767 to derivative financial instruments in its balance sheet. The issuance of such shares of common stock was not registered under the Securities Act as such issuance was exempt from registration under Section 4(2) of the Securities Act and Regulation D promulgated thereunder (see Note 3). On February 14, 2013, the Company closed a private placement (the “February Private Placement”) of 3,045,929 shares of common stock, at a purchase price of $3.00 per share, or $9,137,787 in the aggregate, and warrants (the “Warrants”) to purchase up to an aggregate of 1,597,969 shares of common stock with an exercise price of $3.60 per such share underlying any Warrant. The Warrants are deemed to be derivative instruments due to a ratchet provision that adjusts the exercise price if the Company issues additional equity instruments in the future at an effective price per share less than the exercise price then in effect. Upon issuance of the warrants, the Company recorded a liability of $4,505,605 to derivative financial instruments in its balance sheet. The issuance of such shares of common stock was not registered under the Securities Act as such issuance was exempt from registration under Section 4(2) of the Securities Act and Regulation D promulgated thereunder. On August 15, 2013, the Company closed a private placement and sold 5,531,401 shares of the Company’s common stock, at a purchase price of $4.50 per share, or $24,891,303 in the aggregate, and warrants to purchase up to an aggregate of 2,765,701 shares of common stock with an exercise price of $6.00 per share underlying each warrant. The Warrants are deemed to be derivative instruments due to a ratchet provision that adjusts the exercise price if the Company issues additional equity instruments in the future at an effective price per share less than the exercise price then in effect. Upon issuance of the warrants, the Company recorded a liability of $9,201,487 to derivative financial instruments in its balance sheet. The issuance of the shares of common stock in such private placement was not registered under the Securities Act as such issuance was exempt from registration under Section 4(2) of the Securities Act and Regulation D promulgated thereunder. February Registration Rights Agreement On February 14, 2013, in connection with the closing of the February Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the purchasers in the February Private Placement (the “Purchasers”), which sets forth the rights of the Purchasers to have their shares of common stock purchased in the February Private Placement and shares of common stock issuable upon exercise of the Warrants registered with the SEC for public resale. Pursuant to the Registration Rights Agreement, the Company was required to file a Registration Statement on Form S-1 (the “Registration Statement”) with the SEC within 30 days of the date of the Registration Rights Agreement registering the total number of shares of common stock purchased in the February Private Placement and shares of common stock issuable upon exercise of the Warrants. The Company further agreed to use its reasonable efforts to have the Registration Statement declared effective within 60 days after the date of the Registration Rights Agreement (or, in the event of a “full review” by the SEC, within 90 days after the date of the Registration Rights Agreement). The Company has also agreed to use reasonable efforts to maintain the effectiveness of the Registration Statement until all of the securities covered by the Registration Statement have or may be sold by investors under Rule 144 of the Securities Act, without volume or manner- of-sale restrictions. The Registration Rights Agreement provided that in the event the Registration Statement was not filed or declared effective within the prescribed time period or if the Company failed to maintain the effectiveness of the Registration Statement as required for specified time periods, the Company shall pay to the holders of registrable securities, on the date of each such event and on each monthly anniversary thereof until the applicable event is cured, partial liquidated damages equal to 2.0% of the aggregate purchase price paid by such Purchaser in the February Private Placement, up to a maximum of 10.0% of such aggregate purchase price. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Purchaser, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The Company determined, as of the date of the financing transaction, that it was probable that it would not be in a position to cause the registration statement to be declared effective within the contractually defined time period. Accordingly, the Company allocated approximately $360,000 of the proceeds to a registration payment arrangement liability on the date that the financing transaction closed, in accordance with the guidelines of ASC 825-20. As described in Note 3, the Company and the investors who are parties to the registration payment arrangement entered into an the Amended Registration Rights Agreement which provides, among other things, for a waiver of the liquidated damages that the Company incurred under the original terms of the registration payment arrangement described herein. The Company recognized $360,000 as income upon the waiver of the liquidated damages. First Amendment to the February Registration Rights Agreement As described in Note 3, the Company and the investors who participated in the private placement transaction that the Company completed on February 14, 2013 entered into the Amended Registration Rights Agreement which provides, among other things, for (i) a waiver of any and all liquidated damages that the Company incurred for its inability to cause the registration statement to be declared effective within certain contractually defined time-frames stipulated in the original agreement; (ii) a commitment on the part of the investors in the February private placement to participate in the private placement transaction that the Company completed on August 15, 2013; and (iii) a covenant on the part of the Company to proceed with the sale of shares that were issued in the August 15, 2013 private placement transaction. In exchange, the Company paid an aggregate fee of $2,495,256 to these investors consisting of (i) 73,710 shares of the Company’s common stock with an aggregate fair value of $331,695 (based on the selling price of $4.50 per share in the August financing transaction); (ii) cash in the amount of $1,835,000; and (iii) warrants to purchase 98,756 shares of common stock with a fair value of $328,561 that were classified as derivative liability instruments. The investors were also given the option to purchase shares of the Company’s common stock at $4.50 per share as a use of the cash portion of the payment arrangement. Accordingly, $946,196 of the cash portion of the fee was settled in cash and the remainder was settled by the issuance of 197,512, shares. Additionally, the Company paid $103,425 to an investor to whom the Company sold shares in a private placement transaction in January 2013 and who participated in the August 2013 private placement transaction. This payment was settled entirely by the issuance of 20,685 shares of the Company’s common stock at a value of $5.00 per share. The Company recorded the aggregate amount of the payments made to the investors by to allocating approximately $360,000 to the waiver of the original registration payment obligation taken as a charge to operations and the remaining amount of $2,238,681 is treated as reduction of the proceeds received in the August financing transaction. August Registration Rights Agreement On August 15, 2013, in connection with the closing of the August 15, 2013 private placement (the “August Private Placement”), the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the purchasers in the August Private Placement (the “Purchasers”), which sets forth the rights of the Purchasers to have their shares of common stock purchased in the Private Placement and shares of common stock issuable upon exercise of the Warrants registered with the SEC for public resale. Pursuant to the Registration Rights Agreement, the Company was required to file a Registration Statement on Form S-1 (the “Registration Statement”) with the SEC within 30 days of the date of the Registration Rights Agreement registering the total number of shares of common stock purchased in the August Private Placement and shares of common stock issuable upon exercise of the Warrants. The Company further agreed to use its reasonable efforts to have the Registration Statement declared effective within 60 days after the date of the Registration Rights Agreement (or, in the event of a “full review” by the SEC, within 120 days after the date of the Registration Rights Agreement). The Company has also agreed to use reasonable efforts to maintain the effectiveness of the Registration Statement until all of the securities covered by the Registration Statement have or may be sold by investors under Rule 144 of the Securities Act, without volume or manner-of-sale restrictions. The Registration Rights Agreement provided that in the event the Registration Statement was not filed or declared effective within the prescribed time period or if the Company failed to maintain the effectiveness of the Registration Statement as required for specified time periods, the Company shall pay to the holders of registrable securities, on the date of each such event and on each monthly anniversary thereof until the applicable event is cured, partial liquidated damages equal to 2.0% of the aggregate purchase price paid by such Purchaser in the August Private Placement, up to a maximum of 10.0% of such aggregate purchase price. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Purchaser, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. On September 13, 2013, the Company submitted the Registration Statement to the SEC on a confidential basis. The Company determined, as of the date of the financing transaction, that it was probable that it would be in a position to cause the registration statement to be declared effective within the contractually defined time period. The Registration Statement was declared effective by the SEC on December 6, 2013. Incentive Stock Awards Since Inception, the Company entered into various incentive unit agreements for issuances of Incentive Common Shares with certain individuals for future services (see note 16). Preferred Stock On January 25, 2012, the Company, in connection with a January 2012 private placement offered for sale up to 875,000 shares of the Company’s Series A Preferred Shares at approximately $5.71 per share with similar terms and conditions as the amended PPM. From January 1, 2012 through May 14, 2012, the Company sold shares of Series A Preferred Stock (subsequently recapitalized into 326,963 shares of common stock) related to the January 2012 private placement at approximately $5.71 per share, yielding aggregate proceeds of $1,868,354 of which 128,163 shares sold and $732,353 proceeds were from a related party through common ownership. In addition, the Company incurred aggregate fees of $61,677 in connection with the private placement. On May 18, 2012, the Company, in connection with the May 2012 private placement, offered for sale up to 875,000 shares of the Company’s Series A Preferred Stock at approximately $11.43 per share with similar terms and conditions as the amended PPM. On September 20, 2012, the Company amended its May 2012 private placement selling price of the Preferred Shares from approximately $11.43 per share to approximately $3.57 per share as a result of a resolution of the Company's board. This resolution was determined as a result of market conditions. From May 31, 2012 through September 25, 2012, the Company sold shares of the Series A Preferred Stock (subsequently recapitalized into 271,824 shares of common stock) related to May 2012 private placement at approximately $3.57 per share, yielding aggregate proceeds of $970,800 of which 185,024 shares sold and $660,800 proceeds were from a related party through common ownership. In addition, the Company incurred aggregate fees of $12,275 in connection with the private placement. From October 1, 2012 through December 11, 2012, the Company sold shares of the Series A Preferred Stock (subsequently recapitalized into 198,940 shares of common stock) related to May 2012 private placement at approximately $3.57 per Unit, yielding aggregate proceeds of $710,501. Capital Contributions of Common Shares by Founder In April 2012, the Company’s founding stockholder personally transferred 300,000 shares of his common stock to third party consultant for advisory services provided to the company. In September 2012, the Company's founder personally transferred 250,000 shares of his common stock to the former Chief Executive Officer and current member of the Board of Directors. The shares in both of these transactions, which have an aggregate fair value of $4,400,000, are fully vested and non-forfeitable and were recorded as a charge to operations in the accompanying statement of operations. In November 2012 and December 2012, the Company’s founding shareholder personally transferred 275,000 shares of his common stock to several employees. The shares, which had an aggregate fair value of $1,375,000, are fully vested and non-forfeitable and were recorded as a charge to operations in the accompanying statement of operations. Receivables from Shareholders On February 3, 2012, the Company entered into a note receivable with a related party in the amount of $200,000. The note receivable was unsecured, bearing an interest rate of 12% per annum and due to mature on February 3, 2013. The note was originally classified as a reduction of stockholders' equity in the accompanying consolidated balance sheet and later treated as compensation in the amount of $372,900 for the year ended December 31, 2012 Stock Options On May 13, 2013, the Company issued options (the “Options”) to purchase 120,000 shares of common stock with an estimated fair value of $804,732 in connection with an employment agreement with Horacio Plotkin, M.D. (the “Plotkin Employment Agreement”) pursuant to which Dr. Plotkin was appointed as Chief Medical Officer of the Company. The Options vest quarterly in pro rata portions during the 3 years following the effective date of July 1, 2013. The Company valued these Options using the Black-Scholes options pricing model with the following assumptions: risk-free interest rate of .83% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 98.56% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the Options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $8.70 per share. For the year ended December 31, 2013, the Company recognized $170,500 as compensation expense related to the Options. On August 13, 2013, the Company issued options to purchase 50,000 shares of common stock with an estimated fair value of $193,765 to an employee. These options vest quarterly in pro rata portions during the 3 years following the effective date of October 1, 2013. The Company valued these options using the Black- Scholes options pricing model and the following assumption terms: risk-free interest rate of 1.49% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 98.56% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $5.00 per share. For the year ended December 31, 2013, the Company recognized $24,774 as compensation expense related to the Options. On September 9, 2013, the Company issued options to purchase 90,000 shares of common stock with an estimated fair value of $448,354 to two employees. The options vest quarterly in pro rata portions during the 3 years following the effective date of October 1, 2013. The Company valued these options using the Black- Scholes options pricing model and the following assumption terms: risk-free interest rate of 1.71% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 104.78% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $6.20 per share. For the year ended December 31, 2013, the Company recognized $46,268 as compensation expense related to the Options. On December 6, 2013 and December 9, 2013, the Company issued options to purchase 330,000 shares of common stock with an estimated fair value of $2,236,848 to six employees. The options vest quarterly in pro rata portions during the 3 years following the effective date of January 1, 2014. The Company valued these options using the Black-Scholes options pricing model and the following assumption terms: risk-free interest rate of 1.51% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 101.66% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $8.70 and $8.10, respectively, per share. For the year ended December 31, 2013, the Company recognized $50,019 as compensation expense related to the Options. On December 6, 2013, the Company issued options to purchase 51,000 shares of common stock with an estimated fair value of $350,085 to four Board of Directors. The options vest immediately. The Company valued these options using the Black-Scholes options pricing model and the following assumption terms: risk-free interest rate of 1.51% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 101.66% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $8.70 per share. For the year ended December 31, 2013, the Company recognized $350,085 as compensation expense related to the Options. On December 16, 2013, the Company issued options (the “Options”) to purchase 1,080,000 shares of common stock with an estimated fair value of $6,350,400 in connection with an employment agreement with Martin Shkreli (the “Shkreli Employment Agreement”). The options vest quarterly in pro rata portions during the 3 years following the effective date of December 31, 2013. The Company valued these Options using the Black-Scholes options pricing model and the following assumption terms: risk-free interest rate of 1.55% (based on the U.S. Treasury note yield), expected term (in years) of 5.81 (based on guidance provided in SAB 107 that allows the Company to use the simplified method for “plain vanilla” options for this calculation), expected volatility of 101.66% (based on historical stock volatilities of several comparable publicly-traded companies over a period equal to the expected term of the options, as the Company does not have a long trading history to estimate the volatility of its own common stock), and an exercise price equal to the fair value of the stock on the date of issuance of $7.45 per share. For the year ended December 31, 2013, the Company recognized $529,200 as compensation expense related to the Options. The following tables illustrates the Company’s stock option issuances and balances outstanding as of, and during the years ended December 31, 2013 and 2012, respectively: Weighted Average Shares Underlying Exercise Remaining Aggregate Outstanding at January 1, 2013 - - - - Granted 1,721,000 $ 7.66 - $ - Cancelled - - - - Exercised - - - - Outstanding at December 31, 2013 1,721,000 $ 7.66 9.89 $ 172,000 Exercisable at December 31, 2013 172,667 $ 7.85 9.86 $ 14,333 The weighted average grant date fair value of option granted during the year ended December 31, 2013 is $6.03 The aggregate intrinsic value of stock options outstanding and exercisable was calculated based on a closing stock price of $7 on December 31, 2013. Unrecognized compensation cost associated with unvested options amounts to $9, 213,338, as of December 31, 2013, which will be expensed over a weighted average remaining vesting period of 2.7 years. Share based compensation For the year ended December 31, 2013, the Company issued 359,000 shares to consultants. The weighted average fair value of the shares issued is $6.92. The Compensation expense for these shares was determined based on the closing market price of the Company’s stock at the date of grant. Compensation expense for the year ended December 31, 2013 amounted to $2,485,875. Stock Repurchases In the fourth quarter of 2013, the Company repurchased 130,790 shares of its common stock for an aggregate purchase price of $957,272. The Company currently recognizes such repurchased common stock as treasury stock.

INCENTIVE SHARES

INCENTIVE SHARES	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
INCENTIVE SHARES	NOTE 16. INCENTIVE SHARES On March 31, 2011, the Company granted 1,849,300 incentive shares to several executive and non-executive employees, and certain consultants, with an aggregate fair value of $7,397,200 or $4 per share. The incentive shares vested on the final day of each calendar quarter over three years, commencing on June 30, 2011. On September 11, 2012, the Company accelerated the vesting of 938,175 shares issued to its founder and Chief Executive Officer, which resulted in a charge of $3,216,600 included in compensation and related costs in the accompanying statement of operations. In August and November 2011, the Company granted an aggregate of 290,000 incentive shares to two consultants, with an aggregate fair value of $1,160,000 or $4 per share, for consulting services. The incentive shares vested on the final day of each calendar quarter over three years, commencing on June 30, 2011 and December 31, 2011. In January 2012, the Company granted 826,600 incentive shares to the Chief Executive Officer, an employee and a consultant, with an aggregate fair value of $9,919,200 or $12 per share. The incentive shares vested on the final day of each calendar quarter over three years, commencing on March 31, 2012. On September 11, 2012, the Company immediately vested the Chief Executive Officer’s unvested incentive shares totaling 28,185 for continuing services. On December 11, 2012, the Chief Executive Officer’s remaining unvested incentive shares totaling 573,015 were vested immediately due to the merger, which resulted in an aggregate charge of $7,214,400 included in compensation and related costs in the accompanying statement of operations. On March 7, 2012, the Company granted 83,333 incentive shares to a third party consultant, with an aggregate fair value of $2,000,000 or approximately $24 per share, for consulting services. The incentive shares vested (i) 50% immediately and (ii) on the final day of each calendar quarter over two years, commencing on March 31, 2012. On July 7, 2012, the Company granted 43,750 incentive shares to an employee, with an aggregate fair value of $375,000 or approximately $8.6 per share. The incentive shares vested on the final day of each calendar quarter over three years, commencing on September 30, 2012. In December 2012, the employee was terminated and the shares were accordingly forfeited. Effective May 20, 2013, the Company entered into an employment agreement with Marc L. Panoff (the “Panoff Employment Agreement”) pursuant to which Mr. Panoff was appointed as Chief Financial Officer and Chief Accounting Officer of the Company. In accordance with the terms of the Panoff Employment Agreement, Mr. Panoff was granted 120,000 shares with an estimated fair value of $768,000 on May 20, 2013 of restricted common stock of the Company, a pro rata portion of which vest quarterly beginning on December 31, 2013 during the 3 years following the effective date. On July 1, 2013, the Company granted 15,000 units of restricted common stock of the Company to an employee with an estimated fair value of $75,000. The stock will vest quarterly in pro rata portions beginning September 30, 2013 during the 3 years following the grant date. For the year ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized $986,575 ($253,682 to employees and $732,893 to non-employees), $22,410,222, and $25,295,054 as compensation expense related to incentive shares granted in the consolidated statements of operations, respectively. Share compensation for non-employee awards subject to vesting is being accrued at current fair value. As of December 31, 2013, there was approximately $1,105,967 of unrecognized compensation cost related to incentive shares issued. This amount is expected to be recognized over a weighted average of 2.19 years. The Company issued these shares with an initial vesting period of 2 to 3 years. Employee – Non Employee – Total number of Weighted Average number of shares number of shares shares Fair Value Unvested March 11, 2011 (“inception”) - $ - Granted 1,758,300 381,000 2,139,300 4.00 Vested (431,240 ) (59,835 ) (491,075 ) 4.00 Forfeited (45,835 ) - (45,835 ) - Unvested December 31, 2011 1,281,225 321,165 1,602,390 4.00 Granted 866,180 87,503 953,683 12.89 Vested (2,048,280 ) (193,672 ) (2,241,952 ) 7.34 Forfeited (46,353 ) - (46,353 ) - Unvested December 31, 2012 52,772 214,996 267,768 3.20 Granted 135,000 200,000 335,000 6.24 Vested (36,724 ) (239,069 ) (275,793 ) 5.44 Forfeited (20,833 ) (37,500 ) (58,333 ) 4.00 Unvested December 31, 2013 130,215 138,427 268,642 $ 6.44 From inception through September 2012, the Company’s share base payments were originally issued as Retrophin LLC Class B incentive units that represent a profits interest up through the date of the Retrophin’s conversation to a C Corporation, which was structured as a tax free exchange transaction. Shares granted as incentive shares were originally subject to certain conditions at the time of grant. Such conditions specified that the occurrence of a Termination Event, as defined in the amended operating agreement the Company shall have the right, but not the obligation, to repurchase, all, of the vested incentive shares owned by such incentive shareholder, at a purchase price based on the fair market value of the incentive shares determined in good faith by the Board of Directors. The aforementioned repurchase option was rescinded upon the Company’s conversion to a corporation.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 17. INCOME TAXES The components of the provision (benefit) for income taxes, in the consolidated statement of operations are as follows (in thousands): 2013 2012 Current Federal $ - $ - State - - - - Deferred Federal (6,293 ) (1,173 ) State (3,435 ) (733 ) (9,728 ) (1,906 ) Total (9,728 ) (1,906 ) Change in valuation allowance 9,804 1,906 Income tax (benefit) 76 - Total $ - $ - A reconciliation of the statutory federal income tax expense (benefit) to the effective tax rate is as follows: 2013 2012 Statutory rate - federal -35.00 % -35.00 % State taxes, net of federal benefit -6.70 % -1.81 % Change in FV of derivative liability (warrants) 10.46 % 0.00 % Stock Based Compensation related to profits interest 2.30 % 9.52 % Other 0.17 % 1.62 % Partnership losses preceding conversion 0.00 % 19.39 % Change in valuation allowance 29.00 % 6.28 % Income tax provision (benefit) 0.23 % 0.00 % The tax effects of "temporary differences" giving rise to deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands): 2013 2012 Net operating loss and capital loss carryforward $ 11,832 $ 2,748 Intangible assets (2,999 ) (466 ) Other 610 (376 ) Valuation allowance (12,044 ) (1,906 ) Total Deferred tax liability $ (2,601 ) $ - From the Company’s inception in March 11, 2011 to September 20, 2012, the Company was not subject to federal and state income taxes since it was operating as a Limited Liability Company (LLC). On September 20, 2012, the Company converted from an LLC to a C corporation and, as a result, became subject to corporate federal and state income taxes. This conversion is considered a recapitalization of the equity structure of the Company and was treated as a nontaxable transaction. As a result of the conversion to a taxable entity, the Company recorded a deferred tax liability on the balance sheet and in income tax expense as of the date of the change in tax status in the amount of $1,079,000 related to the technology license. For the periods ended December 31, 2012 and 2013, the Company incurred net operating losses and, accordingly, no federal current provision for income taxes has been recorded. As a result of indefinite-lived intangibles that are not subject to amortization for tax purposes, the Company recorded a deferred provision for the period ended December 31, 2013. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets including NOL carryovers. At December 31, 2013, the Company had approximately $25.3million of federal, state and local net operating losses. The Company's utilization of the net operating loss carryforwards may be subject to annual limitations due to the ownership change limitations provided by Internal Revenue Code (IRC) Section 382 and similar state provisions. Pursuant to IRC Section 382, the annual use of the Company’s net operating loss credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The annual limitations may result in the expiration of net operating losses and credits prior to utilization. The annual limitation is determined based upon the fair market value of the Company as of the date of such ownership change. Based on the value of the Company at all relevant dates, the computed annual limitation that would result from an ownership change of the Company is not expected to prevent us from utilizing our net operating losses prior to their expiration if we can generate sufficient taxable income to do so in the future. The net operating loss carry forwards, if not utilized, will begin to expire in 2032 for federal purposes. The Company recorded a deferred income tax provision of approximately $76,000 in the year ended December 31, 2013 related to the different book and tax treatment for other intangible assets. For tax purposes, intangible assets are subject to different amortization allowances than for book purposes. Further, pursuant to the guidance in FASB ASC 740-10-55, the Company has stepped-up the basis of its intangible assets by $2,525,124 and has recorded a deferred tax liability in the same amount, to account for the book/tax basis difference resulting from the Kyalin acquisition. The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. The Company’s income tax returns are open to examination by federal, state and foreign tax authorities, generally for the years ended December 31, 2011 and later. The Company has no amount recorded for any unrecognized tax benefits as of December 31, 2013 and 2012, nor did the Company record any amount for the implementation of ASC 740. The Company’s policy is to record estimated interest and penalty related to the underpayment of income taxes or unrecognized tax benefits as a component of its income tax provision. During the years ended 2013 and 2012, the Company did not recognize any interest or penalties in its statements of operations and there are no accruals for interest or penalties at December 31, 2013 or 2012.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18. SUBSEQUENT EVENTS In accordance with ASC 855-10, Company management reviewed all material events through the date of this report. On February 28, 2014, the Company amended its lease agreement for its offices located in Carlsbad, CA. The Company increased its Carlsbad offices by approximately 3,800 square feet of office space for approximately $110,000 of additional annual base rent plus rent escalations, common area maintenance, insurance, and real estate taxes under a lease agreement expiring in June 2017. Public Offering On January 9, 2014, the Company completed a public offering of 4,705,882 shares of common stock at a price of $8.50 per share. The Company received net proceeds from the offering of $37,399,997, after deducting the underwriting discount and other estimated offering expenses. Acquisition of Manchester Pharmaceuticals, LLC On March 26, 2014, the Company acquired 100% of the outstanding membership interests of Manchester Pharmaceuticals, LLC (“Manchester” or “acquiree”), a privately-held specialty pharmaceutical company that focuses on treatments for rare diseases. The acquisition of Manchester expands the Company’s ability to address the special needs of patients with ultra-rare diseases. Under the terms of the agreement, the Company paid $29.5 million upon closing, of which $3.2 million was paid by Retrophin Therapeutics International LLC, a newly formed indirect wholly owned subsidiary, for rights of product sales outside of the United States. The Company entered into a promissory note with Manchester principals for $33 million to be paid in three equal installments of $11 million within three, six, and nine months after closing. Additional contingent payments will be made based on product sales. The Company expects to raise additional funds through a public equity offering, a private equity offering, and/or debt financing to satisfy its short term obligations. The financial statements of the acquiree are not practicable to prepare at the time of filing due to the acquiree being privately held and not maintaining financial statements in accordance with U.S. GAAP. The initial accounting for the business combination is not yet complete and the Company is still performing procedures to determine the appropriate accounting. As such, the Company is unable to make the following disclosures, (i) pro forma data, (ii) purchase price allocation, (iii) expenses of the acquisition, and (iv) revenue and earnings of the acquiree since the acquisition date. Exercise of Warrants Subsequent to year end, an aggregate of 798,391 warrants were exercised for a total of $3,830,316 in cash received by the Company. Covered Short Sales Subsequent to December 31, 2013, the Company purchased $1,019,456 in marketable securities of thirteen publicly traded companies to “cover” securities sold, not yet purchased held as of December 31, 2013. As of the date of this filing, the Company has realized a gain on securities sold, not yet purchased in the amount of $45,885. Stock Repurchases Subsequent to December 31, 2013, the Company repurchased 248,801 shares of its common stock for an aggregate purchase price of $2,257,336. The Company currently recognizes such repurchased common stock as treasury stock. Consulting Agreements On January 14, 2014, the Company entered into an agreement with a consultant to serve as an advisor to the Company. The Company granted 14,000 shares of common stock payable as follows (i) 3,500 shares of common stock issued on April 1, 2014, (ii) 3,500 shares of common stock issued on July 1, 2014, (iii) 3,500 shares of common stock issued on October 1, 2014, (iv) 3,500 shares of common stock issued on January 1, 2015. In addition, the Consultant shall receive $12,500 per month. The agreement expires on January 13, 2015. On February 14, 2014, the Company entered into an agreement with a consultant to serve as an advisor to the Company. The Company granted 66,000 shares of common stock payable as follows (i) 16,500 shares of common stock issued on March 31, 2014, (ii) 16,500 shares of common stock issued on June 30, 2014, (iii) 16,500 shares of common stock issued on September 30, 2014, (iv) 16,500 shares of common stock issued on December 31, 2014. In addition, the Consultant shall receive $200,000 upon the execution of the agreement. The agreement expires on December 31, 2014. In March 2014, the Company entered into an agreement with a consultant to serve as an advisor to the Company. In exchange for the services, the Company issued 200,000 shares of common stock. Bonus On February 24, 2014, the Company’ Board of Directors approved an aggregate cash bonus pool of $1,100,000 to officers and employees of record as of December 31, 2013. Employee Equity Issuance Subsequent to year end, the Company issued 400,000 shares of restricted common stock to three officers and 1,210,000 options to purchase shares of the Company’s common stock to four officers and other employees of the Company. Securities sold, not yet purchased As of the date of this filing, the Company has $1,218,800 and $498,146 of securities sold not yet purchased and unrealized loss related to securities sold, not yet purchased, respectively.

SUMMARY OF SIGNIFICANT ACCOUN27

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiary in conformity with United States of America generally accepted accounting principles (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation.
Cash	Cash For purposes of the statement of cash flows, the Company considers cash instruments with maturities of less than three months when purchased to be cash equivalents. There are no cash equivalents as of the balance sheet date. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits.
Marketable Securities	Marketable Securities The Company accounts for marketable securities held as “available-for-sale” in accordance with ASC 320, “Investments Debt and Equity Securities” (“ASC 320”). The Company classifies these investments as current assets and carry them at fair value. Unrealized gains and losses are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income. Realized gains or losses on marketable security transactions are reported in earnings and computed using the specific identification of cost basis. Marketable securities are maintained at one financial institution and are governed by the Company’s investment policy as approved by our Board of Directors. Fair values of marketable securities are based on quoted market prices. Valuation of marketable securities are further describe in Note 5.
Securities Sold, Not Yet Purchased	Securities Sold, Not Yet Purchased Securities sold, not yet purchased consist of marketable securities that the Company has sold short. In order to facilitate a short sale, the Company borrows the securities from another party and delivers the securities to the buyer. The Company will be required to "cover" its short sale in the future through the purchase of the security in the market at the prevailing market price and deliver it to the counterparty from which it borrowed. The Company is exposed to a loss to the extent that the security price increases during the time from when the Company borrowed the security to when the Company purchases it in the market to cover the short sale. The Company accounts for securities sold, not yet purchased in accordance with ASC 815 – Derivative and Hedging (“ASC 815”), which states such transactions have two of the three characteristics of a derivative instrument and do not generally involve derivative instruments. Securities sold, not yet purchased are presented on the consolidated balance sheets with gains and losses reported in realized and unrealized gains on marketable securities on the consolidated statement of operations and comprehensive loss.
Restricted Cash	Restricted Cash The Company holds restricted cash as a rent guarantee on an operating lease through September 2016.
Employee Stock-Based Compensation	Employee Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, “Stock Compensation” (“ASC 718”). ASC 718 addresses all forms of share- based payment (“SBP”) awards including shares issued under employee stock purchase plans and stock incentive shares. Under ASC 718 awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest and will result in a charge to operations.
Non-Employee Stock-Based Compensation	Non-Employee Stock-Based Compensation The Company accounts for equity instruments issued to non-employees in accordance with ASC 505, “Share Based Payments to Non-Employees” (“ASC 505”), and ASC 718 which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instruments vest. Non-employee stock-based compensation charges are being amortized over their respective contractual vesting periods.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payments, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets and estimating the fair value of long-lived assets to assets whether impairment charges may apply.
Research and Development Costs	Research and Development Costs The Company develops new products through research and development and the licensing and acquisition of third-party businesses and technologies. Research and development costs are charged to operations as incurred and consist primarily of internal and external expenses related to conducting clinical trials, pre-clinical studies, regulatory activities, consulting, contract research and development, and compensation. For the years ended December 31, 2013 and 2012, and for the period from March 11, 2011 (inception) through December 31, 2013, the Company recognized $7,084,009, $662,502 $7,978,522, respectively, of research and development costs.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. Since the Company was incorporated on March 11, 2011, all of its years of operations will be subject to examination. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material changes to its consolidated financial position. The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest as of or during the period from March 11, 2011 (inception) through December 31, 2013. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. Prior to conversion into a corporation on September 20, 2012, as a limited liability company, the Company was treated as a partnership for federal and state income tax purposes. Accordingly, no provision has been made for federal and state income taxes in the accompanying financial statements for any periods preceding September 20, 2012, since all items of income or loss are required to be reported on the income tax returns of the members, who are responsible for any taxes thereon. Profits and losses are allocated based upon capital in accordance with the permissible methods under Internal Revenue Code Section 704. Further, the Company incurred losses since inception through September 20, 2012, that would have resulted in the recognition of deferred tax assets that would have been fully reserved had the Company been subject to income taxes. The Company is subject to the New York City Unincorporated Business Tax through September 19, 2012. Subsequent to the Company’s conversion to a corporation from a limited liability company on September 20, 2012, the Company reports and pays taxes based on its income or loss.
Foreign Currency Translation and Remeasurement	Foreign Currency Translation and Remeasurement The Company accounts for foreign currency translation and remeasurement in accordance with ASC 830, “Foreign Currency Matters” (“ASC 830”). Under ASC 830, currency assets and liabilities are translated into the reporting currency, US Dollars, using period end rates of exchange and the related translation adjustments are recorded as a separate component of accumulated other comprehensive income. Functional statements of operations amounts expressed in functional currencies are translated using average exchange rates for the respective periods. Remeasurement adjustments and gains or losses resulting from foreign currency transactions are recorded as foreign exchange gains or losses in the consolidated statements of operations.
Patents	Patents The Company capitalized external cost, such as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company expense cost associated with maintaining and defending patents subsequent to their issuance in the period incurred. The Company amortizes patent cost once issued on a straight-line basis over the estimate useful lives of the patents. The Company assesses the carrying amounts of its patents for potential impairment when events or changes in circumstances indicate that the carrying amounts of our patents may not be recoverable. As of December 31, 2013 and 2012, patents costs of $49,775 and $18,093, respectively, are included in the accompanying consolidated balance sheets.
Long-Lived Assets	Long-Lived Assets The Company accounts for long-lived assets in accordance with ASC 360, “Long-lived assets, other than goodwill, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or any other significant adverse change that would indicate that the carrying amount of an asset or group of assets may not be recoverable. Application of alternative assumptions, such as changes in estimate of future cash flows, could produce significantly different results. Because of the significance of the judgments and estimation processes, it is likely that materially different amounts could be recorded if we used different assumptions or if the underlying circumstances were to change. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Basic and diluted Net Loss Per Share	Basic and diluted Net Loss Per Share Basic and diluted net loss per share has been computed by dividing net loss by the weighted average number of common shares outstanding during the period. All potentially dilutive common shares have been excluded since their inclusion would be anti-dilutive. An aggregate of 4,462,426 and 0 warrants were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because their inclusion would have an anti-dilutive effect for the periods presented. An aggregate of 172,667 and 0 stock options were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because they would have an anti-dilutive effect for the periods presented. An aggregate of 168,643 and 267,768 incentive shares were excluded from the computation of diluted net loss per common share for the years ended December 31, 2013 and 2012, respectively, because they were contingent shares subject to recall. On January 9, 2014, the Company completed a public offering of 4.7 million shares of common stock at a price of $8.50 per share (see Note 18). Subsequent to year end, an aggregate of 798,391 warrants were exercised for a total of $3,830,316 in cash received by the Company (see Note 18).
Derivative Instruments	Derivative Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company calculates the fair value of the financial instruments using the Binomial Lattice options pricing model at inception and on each subsequent valuation date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period (see Note 6 and Note 7).
Joint and Several Liability Arrangements	Joint and Several Liability Arrangements The Company measures obligations resulting from joint and several liability arrangements as the sum of the amount that the Company has a) contractually agreed to pay, and b) any additional amounts that the Company expects to pay on behalf of its co-obligors.
Financial Instruments and Fair Value	Financial Instruments and Fair Value The Company accounts for financial instruments in accordance with ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC Topic 820”). ASC Topic 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described below: Level 1 Level 2 Level 3 In estimating the fair value of the Company’s marketable securities available-for-sale and securities sold, not yet purchased, the Company used quoted prices in active markets (see Note 5 and Note 7). In estimating the fair value of the Company’s derivative liabilities, the Company used the Binomial Lattice pricing model (see Note 6 and Note 7). Financial assets with carrying values approximating fair value include cash as well as marketable securities, deposits on license agreements, prepaid expenses and other current assets. Financial liabilities with carrying values approximating fair value include accounts payable and accrued expenses.
Treasury Stock	Treasury Stock Treasury stock is recorded at cost. Issuance of treasury stock is accounted for on a first-in, first-out basis. Differences between the cost of treasury stock and the re- issuance proceeds are charged to additional paid-in capital.
Registration Payment Arrangements	Registration Payment Arrangements The Company accounts for registration payment arrangements in accordance with ASC 825-20, “Registration Payment Arrangements” (“ASC 825-20”) ASC 825- 20 addresses an issuer’s accounting for registration payment arrangements. This pronouncement specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument, should be separately recognized and accounted for as a contingency in accordance with ASC 450-20, “Loss Contingencies” (“ASC 450”).
Reclassifications	Reclassifications Certain prior year financial statement balances have been reclassified to conform to the current year presentation. These reclassifications had no effect on the recorded net loss. The Company reclassified research and development expenses and selling, general, and administrative expenses.
Subsequent Events	Subsequent Events The Company follows the provisions of ASC Topic 855-10, “Subsequent Events” (“ASC 855-10”) relating to subsequent events. This guidance establishes principles and requirements for subsequent events. This guidance defines the period after the balance sheet date during which events or transactions that may occur would be required to be disclosed in a company’s financial statements. The Company has evaluated subsequent events up to the date of issuance of this report.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-04 “Obligations Resulting from Joint and Several Liability Arrangements for Which the Amount at the Reporting Date is Fixed” (“ASU 2013-04”). The guidance in this update is effective for fiscal years beginning after December 15, 2013 with early adoption permitted. The guidance in this update requires companies to measure obligations resulting from joint and several liability arrangements as the sum of the amount the entity has a) contractually agreed to pay, and b) any additional amounts that the entity expects to pay on behalf of its co-obligors. The Company early adopted this guidance in the second quarter of 2013 (Note 3 and Note 13). The FASB has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company has not yet determined the effect of the adoption of this standard and it is not expected to have a material impact on the Company’s consolidated financial position and results of operations. Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a significant effect on the accompanying consolidated financial statements.

RESTATEMENTS OF PREVIOUSLY IS28

RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Restatements Of Previously Issued Consolidated Finacial Statements [Abstract]
Schedule of effects of restatement on affected items within previously reported Consolidated Balance Sheets	Quantitative Impact on Previously Issued Interim and Annual Financial Statements September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Non-derivative liabilities $ 4,935 $ 7,090 $ 13,774 $ 15,129 Derivative financial instruments, warrants 23,853 23,853 25,037 25,037 Total Liabilities 28,788 30,943 38,811 40,166 Additional paid in capital 47,498 46,220 50,189 49,636 Deficit accumulated during the development stage (54,768 ) (55,645 ) (67,436 ) (68,237 ) Stockholder’s deficit $ (7,423 ) $ (9,578 ) $ (18,312 ) $ (19,667 ) Quantitative Impact on Previously Issued Interim Financial Statements March 31, 2013 June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised As Reported As Revised Non-derivative liabilities $ 1,575 $ 1,460 $ 4,229 $ 4,229 $ 4,935 $ 4,935 Derivative financial instruments, warrants 6,957 8,349 6,901 8,283 22,234 23,853 Total Liabilities 8,532 9,809 11,130 12,512 27,169 28,788 Additional paid in capital 34,772 33,620 34,945 33,793 48,650 47,498 Deficit accumulated during the development stage (38,355 ) (38,480 ) (43,404 ) (43,634 ) (54,301 ) (54,768 ) Stockholder’s deficit $ (3,582 ) $ (4,859 ) $ (8,457 ) $ (9,839 ) $ (5,804 ) $ (7,423 )
Schedule of effects of restatement on affected items within previously reported Consolidated Statement of Operations	Quantitative Impact on Previously Issued Interim and Annual Financial Statements September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Selling, General and Administrative $ 3,755 $ 4,631 $ 6,747 $ 6,672 Operating loss (5,155 ) (6,031 ) (11,717 ) (11,642 ) Net loss (11,135 ) (12,011 ) (12,668 ) (12,592 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.78 ) $ (0.73 ) $ (0.73 ) September 30, 2013 December 31, 2013 As Revised* As Restated As Revised* As Restated Selling, General and Administrative $ 10,141 $ 11,017 $ 16,888 $ 17,689 Operating loss (12,255 ) (13,131 ) (23,972 ) (24,773 ) Net loss (21,156 ) (22,033 ) (33,824 ) (34,625 ) Net loss per share, basic and diluted $ (1.65 ) $ (1.72 ) $ (2.38 ) $ (2.44 ) *For matters identified during the fourth quarter of 2013 described in (2) below. (2) As previously discussed in the Form 10-K for the year ended 2013, in the fourth quarter of 2013, the Company discovered that certain warrants issued to a placement agent in connection with our February 14, 2013 Private Placement Offering (“February Private Placement”), were not recorded and certain expenses were misstated in our condensed consolidated financial statements for the first, second, and third quarters of 2013. The misstated expenses include costs related to the February Private Placement, certain accruals, consulting fees, and changes in the fair value of the unrecorded warrants, which required liability classification. Quantitative Impact on Previously Issued Interim Financial Statements March 31, 2013 June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised As Reported As Revised Selling, General and Administrative $ 2,141 $ 1,777 $ 4,495 $ 4,610 $ 3,755 $ 3,755 Operating loss (2,250 ) (1,885 ) (5,100 ) (4,215 ) (5,155 ) (5,155 ) Non-operating loss (2,492 ) (2,982 ) 51 61 (5,743 ) (5,980 ) Net loss (4,742 ) (4,867 ) (5,049 ) (5,154 ) (10,898 ) (11,135 ) Net loss per common share, basic and diluted $ (0.44 ) $ (0.46 ) $ (0.41 ) $ (0.42 ) $ (0.71 ) $ (0.72 ) June 30, 2013 September 30, 2013 As Reported As Revised As Reported As Revised Selling, General and Administrative $ 6,636 $ 6,387 $ 10,391 $ 10,141 Operating loss (7,350 ) (7,100 ) (12,505 ) (12,255 ) Non-operating loss (2,441 ) (2,921 ) (8,184 ) (8,901 ) Net Loss (9,791 ) (10,021 ) (20,689 ) (21,156 ) Net loss per common share, basic and diluted $ (0.85 ) $ (0.87 ) $ (1.62 ) $ (1.65 )

MARKETABLE SECURITIES AND SEC29

MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED (Tables)	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]
Schedule of marketable securities	Cost Unrealized Gains Unrealized Estimated Fair Marketable securities available-for-sale: $ 129,702 $ 3,292 $ - $ 132,994 Securities sold, not yet purchased $ 1,344,622 $ 13,256 $ 126,535 $ 1,457,901

DERIVATIVE FINANCIAL INSTRUME30

DERIVATIVE FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, All Other Investments [Abstract]
Schedule of assumptions for valuation of warrants	As of Date of issuance February 14, 2013 Date of issuance August 14, 2013 Date of issuance August 15, 2013 December 31, 2013 Fair market price of common stock $3.75 $4.50 $4.50 $7.00 Contractual term 5 years 5 years 5 years 4.12 – 4.62 years Risk-free interest rate 0.86% 1.48% 1.48% 1.39% Expected volatility 101% 106% 106% 93%-97%
Schedule of derivative warrant issuances and balances outstanding	Weighted Average Warrants Exercise Price Fair Value Outstanding at December 31, 2011 - $ - $ - Issued - - - Canceled - - - Exercised - - - Outstanding at December 31, 2012 - $ - $ - Issued 4,782,249 5.04 3.13 Canceled - - - Exercised - - - Outstanding at December 31, 2013 4,782,249 $ 5.04 $ 5.23
Schedule of derivative warrants outstanding	Weighted Average Remaining Contractual Exercise Price Number of Warrants Life (years) Number Exercisable $ 3.60 1,917,792 4.12 1,917,792 $ 6.00 2,864,457 4.62 2,864,457

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis	As of December 31, 2013 Fair Value Hierarchy at December 31, 2013 Quoted prices in Significant other Significant Total carrying and active markets observable inputs unobservable estimated fair value (Level 1) (Level 2) inputs (Level 3) Asset: Marketable securities, available-for-sale $ 132,994 $ 132,994 $ - $ - Liabilities: Derivative liability related to warrants $ 25,037,346 $ - $ - $ 25,037,346 Securities sold, not yet purchased $ 1,457,901 $ 1,457,901 $ - $ - Settlement agreement $ 1,155,000 $ 1,155,000 $ - $ -
Schedule of summary of changes in the estimated fair value of the Company's Level 3 liability	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) Balance at January 1, 2013 $ - Issuance of common stock warrants: February 14, 2013 5,407,372 August 14, 2013 328,561 August 15, 2013 9,201,487 Total value upon issuance 14,937,420 Change in fair value of common stock warrant liability 10,099,926 Balance at December 31, 2013 $ 25,037,346

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of indefinite lived intangible assets	Indefinite lived intangible assets as of December 31, 2013 consist of the following: Syntocinon License $ 5,000,000 Carbetocin Assets 5,560,355 Total $ 10,560,355
Schedule of Indefinite lived intangible asset	December 31, 2013 Gross Carrying Accumulated Net Book Value Lingand License $ 2,300,000 $ (323,980 ) $ 1,976,020 Patent Costs* 49,775 - 49,775 Total $ 2,349,775 $ (323,980 ) $ 2,025,795 December 31, 2012 Gross Carrying Accumulated Net Book Value Lingand License $ 2,300,000 $ (121,383 ) $ 2,178,617 Patent Costs* 18,093 - 18,093 Total $ 2,318,093 $ (121,383 ) $ 2,196,710 *Patent costs will be amortized when a patent is procured and a life is assigned to the asset
Schedule of amortization expense	As of December 31, 2013, amortization expense for the next five years is expected to be as follows: 2014 $ 202,597 2015 202,597 2016 202,597 2017 202,597 2018 202,597 thereafter 1,012,810 Total $ 2,025,795

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
Schedule of accrued expenses	December 31, 2013 December 31, 2012 Compensation related costs $ 1,144,983 $ 1,022,716 Research and development 1,035,875 679,800 Business development 300,000 - License fee 150,000 - Accounting and legal fees 75,000 563,380 Finder’s fee - 100,000 Other - 11,250 Interest - 90,650 Other operating expenses 1,428,837 - Offering costs 746,739 - Total $ 4,881,434 $ 2,467,796

SELLING, GENERAL, AND ADMINIS34

SELLING, GENERAL, AND ADMINISTRATIVE (Tables)	12 Months Ended
	Dec. 31, 2013
Selling General And Administrative
Schedule of selling, general, and administrative expenses	For the period from March 11, 2011 (inception) through December 31, December 31, December 31, 2013 2012 2013 Professional fees (inclusive of share base compensation $1,485,393, $6,397,372, and $8,137,097) $ 5,600,455 $ 9,035,702 $ 15,249,423 Other 7,564,241 725,263 8,386,902 Compensation and related costs (inclusive of share base compensation 4,274,743 18,133,550 24,729,314 Technology license contingent fees 250,000 1,700,000 1,950,000 Total selling, general, and administrative expenses $ 17,689,439 $ 29,594,515 $ 50,315,639

RESEARCH AND DEVELOPMENT (Table

RESEARCH AND DEVELOPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]
Schedule of research and development expenses	For the period from March 11, 2011 through December 31, December 31, December 31, 2013 2012 2013 External service provider costs: Sparsentan $ 2,443,273 $ 297,833 $ 2,619,723 RE-024 1,548,957 124,635 1,673,592 Weg license in process R&D (Note 14) 1,000,000 - 1,000,000 Syntocinon 250,540 - 250,540 RE-034 230,279 - 230,279 General 159,080 240,034 493,569 Other product candidates 117,771 - 376,710 Total external service provider costs: 5,749,900 662,502 6,644,413 Internal personnel costs (inclusive of share base compensation $259,076, $0, and $259,076): 1,334,109 - 1,334,109 Total research and development $ 7,084,009 $ 662,502 $ 7,978,522

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Schedule of contract commitments	The following table summarizes our principal contractual commitments, excluding open orders that support normal operations, as of December 31, 2013: Research and Year Ending December 31, Donations Consultants Operating Leases 2014 $ 4,560,092 $ 831,660 $ 777,538 2015 2,950,294 - 811,149 2016 - - 724,292 2017 - - 12,850 2018 - - - 2019 and thereafter - - - Total $ 7,510,386 $ 831,660 $ 2,325,829

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]
Schedule of stock option issuances and balances outstanding	Weighted Average Shares Underlying Exercise Remaining Aggregate Outstanding at January 1, 2013 - - - - Granted 1,721,000 $ 7.66 - $ - Cancelled - - - - Exercised - - - - Outstanding at December 31, 2013 1,721,000 $ 7.66 9.89 $ 172,000 Exercisable at December 31, 2013 172,667 $ 7.85 9.86 $ 14,333

INCENTIVE SHARES (Tables)

INCENTIVE SHARES (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of incentive shares	Employee – Non Employee – Total number of Weighted Average number of shares number of shares shares Fair Value Unvested March 11, 2011 (“inception”) - $ - Granted 1,758,300 381,000 2,139,300 4.00 Vested (431,240 ) (59,835 ) (491,075 ) 4.00 Forfeited (45,835 ) - (45,835 ) - Unvested December 31, 2011 1,281,225 321,165 1,602,390 4.00 Granted 866,180 87,503 953,683 12.89 Vested (2,048,280 ) (193,672 ) (2,241,952 ) 7.34 Forfeited (46,353 ) - (46,353 ) - Unvested December 31, 2012 52,772 214,996 267,768 3.20 Granted 135,000 200,000 335,000 6.24 Vested (36,724 ) (239,069 ) (275,793 ) 5.44 Forfeited (20,833 ) (37,500 ) (58,333 ) 4.00 Unvested December 31, 2013 130,215 138,427 268,642 $ 6.44

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Schedule of income tax provision	2013 2012 Current Federal $ - $ - State - - - - Deferred Federal (6,293 ) (1,173 ) State (3,435 ) (733 ) (9,728 ) (1,906 ) Total (9,728 ) (1,906 ) Change in valuation allowance 9,804 1,906 Income tax (benefit) 76 - Total $ - $ -
Schedule of reconciliation of the statutory federal income tax expense (benefit)	2013 2012 Statutory rate - federal -35.00 % -35.00 % State taxes, net of federal benefit -6.70 % -1.81 % Change in FV of derivative liability (warrants) 10.46 % 0.00 % Stock Based Compensation related to profits interest 2.30 % 9.52 % Other 0.17 % 1.62 % Partnership losses preceding conversion 0.00 % 19.39 % Change in valuation allowance 29.00 % 6.28 % Income tax provision (benefit) 0.23 % 0.00 %
Schedule of deferred tax assets and liabilities	2013 2012 Net operating loss and capital loss carryforward $ 11,832 $ 2,748 Intangible assets (2,999 ) (466 ) Other 610 (376 ) Valuation allowance (12,044 ) (1,906 ) Total Deferred tax liability $ (2,601 ) $ -

DESCRIPTION OF BUSINESS (Detail

DESCRIPTION OF BUSINESS (Detail Textuals) - Dec. 12, 2012 - 2012 Merger - USD ($)	Total
Description Of Business [Line Items]
Conversion of stock, description	Each Common stockholder of Former Retrophin received 5 shares of the Company's common stock
Number of shares converted	1
Number of shares issued	5
Class "A" Preferred shares
Description Of Business [Line Items]
Conversion of stock, description	Each Class A Preferred stockholder received 7 shares of the Company's common stock
Number of shares converted	1
Number of shares issued	7
Desert Gateway
Description Of Business [Line Items]
Net assets	$ 1,401
Cash	3,721
Trade liabilities	$ 2,320

RESTATEMENTS OF PREVIOUSLY IS41

RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Details) - USD ($)	Dec. 31, 2013		Oct. 02, 2013		Sep. 30, 2013		Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Mar. 12, 2011	Mar. 11, 2011
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total liabilities	$ 40,165,777	[1]							$ 5,799,080
Additional paid in capital	49,635,502	[1]							30,203,402
Deficit accumulated during the development stage	(68,236,996)	[1]							(33,612,112)
Stockholder's deficit	(19,666,898)	[1]							$ (3,407,815)	$ (536,285)
As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Non-derivative liabilities	13,774,000	[2]			$ 4,935,000	[2]	$ 4,229,000	$ 1,460,000
Derivative financial instruments, warrants	25,037,000	[2]			23,853,000	[2]	8,283,000	8,349,000
Total liabilities	38,811,000	[2]			28,788,000	[2]	12,512,000	9,809,000
Additional paid in capital	50,189,000	[2]			47,498,000	[2]	33,793,000	33,620,000
Deficit accumulated during the development stage	(67,436,000)	[2]			(54,768,000)	[2]	(43,634,000)	(38,480,000)
Stockholder's deficit	(18,312,000)	[2]	$ (7,423,000)	[2]	(7,423,000)	[2]	(9,839,000)	(4,859,000)
As Restated
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Non-derivative liabilities	15,129,000				7,090,000
Derivative financial instruments, warrants	25,037,000				23,853,000
Total liabilities	40,166,000				30,943,000
Additional paid in capital	49,636,000				46,220,000
Deficit accumulated during the development stage	(68,237,000)				(55,645,000)
Stockholder's deficit	$ (19,667,000)		$ (9,578,000)		(9,578,000)
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Non-derivative liabilities					4,935,000		4,229,000	1,575,000
Derivative financial instruments, warrants					22,234,000		6,901,000	6,957,000
Total liabilities					27,169,000		11,130,000	8,532,000
Additional paid in capital					48,650,000		34,945,000	34,772,000
Deficit accumulated during the development stage					(54,301,000)		(43,404,000)	(38,355,000)
Stockholder's deficit					$ (5,804,000)		$ (8,457,000)	$ (3,582,000)
[1]	(As Restated)
[2]	For matters identified during the fourth quarter of 2013 described in (2) below.

RESTATEMENTS OF PREVIOUSLY IS42

RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Details 1) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended			34 Months Ended
	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2013		Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013	[1]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Selling, General and Administrative											$ 17,689,439	[1]	$ 29,594,515	$ 50,315,639
Operating loss											(24,773,448)	[1]	(30,257,017)	(58,294,161)
Net loss										$ (3,268,256)	$ (34,624,884)	[1]	$ (30,343,856)	$ (68,236,996)
Net loss per share, basic and diluted											$ (2.44)	[1]	$ (8.29)
As Revised
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Selling, General and Administrative	$ 6,747,000	[2]	$ 3,755,000	[2]	$ 4,610,000	$ 1,777,000	$ 6,387,000	$ 10,141,000	[2]		$ 16,888,000	[2]
Operating loss	(11,717,000)	[2]	(5,155,000)	[2]	(4,215,000)	(1,885,000)	(7,100,000)	(12,255,000)	[2]		(23,972,000)	[2]
Non-operating loss			(5,980,000)		61,000	(2,982,000)	(2,921,000)	(8,901,000)
Net loss	$ (12,668,000)	[2]	$ (11,135,000)	[2]	$ (5,154,000)	$ (4,867,000)	$ (10,021,000)	$ (21,156,000)	[2]		$ (33,824,000)	[2]
Net loss per share, basic and diluted	$ (0.73)	[2]	$ (0.72)	[2]	$ (0.42)	$ (0.46)	$ (0.87)	$ (1.65)	[2]		$ (2.38)	[2]
As Restated
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Selling, General and Administrative	$ 6,672,000		$ 4,631,000					$ 11,017,000			$ 17,689,000
Operating loss	(11,642,000)		(6,031,000)					(13,131,000)			(24,773,000)
Net loss	$ (12,592,000)		$ (12,011,000)					$ (22,033,000)			$ (34,625,000)
Net loss per share, basic and diluted	$ (0.73)		$ (0.78)					$ (1.72)			$ (2.44)
As Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Selling, General and Administrative			$ 3,755,000		$ 4,495,000	$ 2,141,000	$ 6,636,000	$ 10,391,000
Operating loss			(5,155,000)		(5,100,000)	(2,250,000)	(7,350,000)	(12,505,000)
Non-operating loss			(5,743,000)		51,000	(2,492,000)	(2,441,000)	(8,184,000)
Net loss			$ (10,898,000)		$ (5,049,000)	$ (4,742,000)	$ (9,791,000)	$ (20,689,000)
Net loss per share, basic and diluted			$ (0.71)		$ (0.41)	$ (0.44)	$ (0.85)	$ (1.62)
[1]	(As Restated)
[2]	For matters identified during the fourth quarter of 2013 described in (2) below.

RESTATEMENTS OF PREVIOUSLY IS43

RESTATEMENTS OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Detail Textuals)

Jan. 14, 2014USD ($)

Aug. 29, 2013USD ($)

Dec. 31, 2013USD ($)shares

Dec. 31, 2013USD ($)Agreement

Dec. 31, 2012USD ($)

Dec. 31, 2013USD ($)

Sep. 30, 2013USD ($)

Jun. 30, 2013USD ($)

Mar. 31, 2013USD ($)

Related Party Transaction [Line Items]

Cash payments

$ 300,000

$ 13,200

[1]

$ 33,300

$ 46,500

[1]

Professional fees

$ 12,500

5,600,455

$ 9,035,702

15,249,423

Legal fees

150,000

Cumulative loss

$ (68,236,996)

[1]

(68,236,996)

[1]

$ (33,612,112)

(68,236,996)

[1]

As Restated

Related Party Transaction [Line Items]

Cumulative loss

(68,237,000)

(68,237,000)

(68,237,000)

$ (55,645,000)

As Revised

Related Party Transaction [Line Items]

Cumulative loss

$ (67,436,000)

[2]

(67,436,000)

[2]

$ (67,436,000)

[2]

$ (54,768,000)

[2]

$ (43,634,000)

$ (38,480,000)

Consulting Agreements

Related Party Transaction [Line Items]

Professional fees

135,000

Legal fees

$ 165,000

Number of agreements | Agreement

2

Consulting Agreements | Mr. Shkreli

Related Party Transaction [Line Items]

Number of common stock issued (in shares) | shares

346,500

Cash payments

$ 200,000

[1]

(As Restated)

[2]

For matters identified during the fourth quarter of 2013 described in (2) below.

LIQUIDITY AND FINANCIAL CONDI44

LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT'S PLANS (Detail Textuals) - USD ($)	Jan. 09, 2014	Aug. 15, 2013	Aug. 14, 2013	Aug. 31, 2013	Jan. 31, 2013	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Aggregate fee paid to investors		$ 2,495,256
Number of shares issued in transaction		73,710
Common stock with an aggregate fair value							$ 30,936,748	[1]	$ 3,475,703	$ 35,175,123	[1]
Sale of Stock, Price Per Share				$ 5
Number of common stock called by warrants		98,756
Proceeds from private placement							30,900,000
Issuance of common stock to investors, per share amount				$ 5
Net loss						$ (3,268,256)	(34,624,884)	[1]	(30,343,856)	(68,236,996)	[1]
Stock-based compensation							986,575		22,410,222	27,300,000
Cash							5,997,307	[1]	11,388	5,997,307	[1]
Working Capital deficit							29,100,000			29,100,000
Accumulated deficit							(68,236,996)	[1]	$ (33,612,112)	(68,236,996)	[1]
Derivative liability related to warrants							$ 25,037,346			$ 25,037,346
Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Common stock with an aggregate fair value	$ 37,399,997
Private Placement Offerings
Subsidiary, Sale of Stock [Line Items]
Sale of Stock, Description of Transaction			(i) a waiver of any and all liquidated damages that the Company incurred for its inability to cause the a registration statement to be declared effective within certain contractually defined time-frames stipulated in the original agreement; (ii) a commitment on the part of the investors in the February private placement to participate in a private placement transaction that the Company completed on August 15, 2013, and (iii) a covenant on the part of the Company to proceed with the sale of shares that were issued under the August 15, 2013 private placement transaction.
Aggregate fee paid to investors			$ 2,495,256
Number of shares issued in transaction		5,531,401	73,710
Common stock with an aggregate fair value			$ 331,695
Sale of Stock, Price Per Share		$ 4.50	$ 4.50
Cash paid on transaction			$ 1,835,000
Number of common stock called by warrants		2,765,701	98,756
Proceeds from private placement		$ 24,891,303	$ 328,561		$ 103,425
Remaining fee settled in cash			$ 946,196
Number of shares issue for remaining fee settled			197,512
Shares issued to investors for inducement to participate in financing			20,685
Issuance of common stock to investors, per share amount			$ 5
Private Placement Offerings | Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Proceeds from private placement	$ 40,000,000
[1]	(As Restated)

LIQUIDITY AND FINANCIAL CONDI45

LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT'S PLANS (Detail Textuals 1) - USD ($)

Oct. 01, 2014

Jan. 09, 2014

Dec. 16, 2013

Dec. 12, 2013

Aug. 29, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Related Party Transaction [Line Items]

Interest rate

5.00%

Proceeds from private placement

$ 30,900,000

Payment for additional settlement agreement

$ 300,000

Realized a gain of sale of Transcept shares

30,936,748

[1]

$ 3,475,703

$ 35,175,123

[1]

UCSD

Related Party Transaction [Line Items]

Research program fees

$ 1,540,000

Payment for fees

0

Research program fees for per quarter

192,500

Accrued expenses

$ 40,082

$ 40,082

Period for written notice

60 days

Transcept

Related Party Transaction [Line Items]

Realized a gain of sale of Transcept shares

$ 235,839

Reserch Agreement

Related Party Transaction [Line Items]

Effective period of SRA

2 years

Licensing agreements | Novartis Pharma AG and Novartis AG

Related Party Transaction [Line Items]

Payment for upfront fee

5,000,000

Licenses annual maintenance fees

3,000,000

Threshold limit for first indication license developmental milestones

34,000,000

Threshold limit for Second indication license developmental milestones

$ 32,000,000

Percentage of royalty on net sales

10%-20

Subsequent Event

Related Party Transaction [Line Items]

Realized a gain of sale of Transcept shares

$ 37,399,997

Chief Executive Officer

Related Party Transaction [Line Items]

Secured promissory note issued to related party

$ 2,284,511

$ 1,691,400

Interest rate

5.00%

Number of share due to cause to be delivered

47,128

Chief Executive Officer | First payment

Related Party Transaction [Line Items]

Secured promissory note issued to related party

$ 593,111

Chief Executive Officer | Second payment

Related Party Transaction [Line Items]

Secured promissory note issued to related party

$ 1,691,400

Dr. Weg | Weg License Agreement

Related Party Transaction [Line Items]

License maintenance and sublicensing fees

$ 1,000,000

[1]

(As Restated)

LIQUIDITY AND FINANCIAL CONDI46

LIQUIDITY AND FINANCIAL CONDITION AND MANAGEMENT'S PLANS (Detail Textuals 2)	Dec. 16, 2013USD ($)	Aug. 15, 2013shares	Mar. 26, 2014USD ($)Installment	Dec. 23, 2013USD ($)$ / sharesshares	Dec. 31, 2013USD ($)	Sep. 30, 2013USD ($)	Jun. 30, 2013USD ($)	Sep. 30, 2012USD ($)
Related Party Transaction [Line Items]
Number of shares issued in transaction | shares		73,710
Proceeds from private placement					$ 30,900,000
Promissory notes payable
Related Party Transaction [Line Items]
Principal amount								$ 30,000
Subsequent Event
Related Party Transaction [Line Items]
Payments to acquire businesses			$ 29,500,000
Manchester Pharmaceuticals, LLC | Subsequent Event
Related Party Transaction [Line Items]
Percentage of voting interests acquired			100.00%
Manchester Pharmaceuticals, LLC | Subsequent Event | Promissory notes payable
Related Party Transaction [Line Items]
Principal amount			$ 33,000,000
Frequency of periodic payments for notes payable			three equal installments
Number of installments | Installment			3
Consecutive payment of notes payable			$ 11,000,000
Retrophin Therapeutics International LLC | Subsequent Event
Related Party Transaction [Line Items]
Payments to acquire businesses			$ 3,200,000
Stock Purchase Agreement | Kyalin Biosciences, Inc
Related Party Transaction [Line Items]
Business acquisition description				(i) $1 million of cash consideration at specified dates; and (ii) up to $4 million of the Company's common stock, par value $0.0001 per share at certain dates and subject to the achievement of certain milestones. Under certain limited circumstances, the Company would be required to pay to the Sellers, in the place of such shares of common stock, an amount of cash equal to one-half (1/2) of the value of the shares of common stock issuable in accordance with the Stock Purchase Agreement
Cash paid on transaction				$ 1,000,000
Number of shares issued in transaction | shares				4,000,000
Business acquisition, share price | $ / shares				$ 0.0001
Mr. Shkreli
Related Party Transaction [Line Items]
Principal amount						$ 1,691,400	$ 2,284,511
Mr. Shkreli | Employment Agreement
Related Party Transaction [Line Items]
Base salary	$ 300,000

SUMMARY OF SIGNIFICANT ACCOUN47

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - USD ($)	Jan. 09, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]
Research and development costs		$ 7,084,009	[1]	$ 662,502	$ 7,978,522	[1]
Patents costs		$ 49,775		$ 18,093	$ 49,775
Warrant
Summary Of Significant Accounting Policies [Line Items]
Warrants exercised		798,391
Proceeds from Issuance of Warrants		$ 3,830,316
Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Issuance of common shares (in shares)	4,705,882
Warrant
Summary Of Significant Accounting Policies [Line Items]
Computation of diluted net loss per common share		4,462,426		0
Stock Option
Summary Of Significant Accounting Policies [Line Items]
Computation of diluted net loss per common share		172,667		0
Incentive Shares
Summary Of Significant Accounting Policies [Line Items]
Computation of diluted net loss per common share		168,643		267,768
[1]	(As Restated)

MARKETABLE SECURITIES AND SEC48

MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED (Details)	Dec. 31, 2013USD ($)
Marketable securities available-for-sale
Cost	$ 129,702
Unrealized Gains	$ 3,292
Unrealized Losses
Estimated Fair Value	$ 132,994
Securities sold, not yet purchased
Cost	1,344,622
Unrealized Gains	13,256
Unrealized Losses	126,535
Estimated Fair Value	$ 1,457,901

MARKETABLE SECURITIES AND SEC49

MARKETABLE SECURITIES AND SECURITIES SOLD, NOT YET PURCHASED (Detail Textuals) - USD ($)	Dec. 31, 2013	[1]	Dec. 31, 2012
Marketable Securities [Abstract]
Securities sold, not yet purchased	$ 1,457,901
[1]	(As Restated)

DERIVATIVE FINANCIAL INSTRUME50

DERIVATIVE FINANCIAL INSTRUMENTS (Details) - 12 months ended Dec. 31, 2013 - $ / shares	Total
Fair market price of common stock	$ 7
Risk-free interest rate	1.39%
Minimum
Contractual term	4 years 1 month 13 days
Expected volatility	93.00%
Maximum
Contractual term	4 years 7 months 13 days
Expected volatility	97.00%
Date of issuance February 14, 2013
Fair market price of common stock	$ 3.75
Contractual term	5 years
Risk-free interest rate	0.86%
Expected volatility	101.00%
Date of issuance August 14, 2013
Fair market price of common stock	$ 4.50
Contractual term	5 years
Risk-free interest rate	1.48%
Expected volatility	106.00%
Date of issuance August 15, 2013
Fair market price of common stock	$ 4.50
Contractual term	5 years
Risk-free interest rate	1.48%
Expected volatility	106.00%

DERIVATIVE FINANCIAL INSTRUME51

DERIVATIVE FINANCIAL INSTRUMENTS (Details 1) - Warrant - $ / shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrants
Outstanding	4,782,249
Outstanding	9,463,375	4,782,249
Derivative
Warrants
Outstanding
Issued	4,782,249
Canceled
Exercised
Outstanding	4,782,249
Weighted Average Exercise Price
Outstanding
Issued	$ 5.04
Canceled
Exercised
Outstanding	$ 5.04
Weighted Average Fair Value
Outstanding
Issued	$ 3.13
Canceled
Exercised
Outstanding	$ 5.23

DERIVATIVE FINANCIAL INSTRUME52

DERIVATIVE FINANCIAL INSTRUMENTS (Details 2) - Dec. 31, 2013 - $ / shares	Total
3.60
Exercise Prices	$ 3.60
Number of Warrants	1,917,792
Weighted Average Remaining Contractual Life (years)	4 years 1 month 13 days
Number Exercisable	1,917,792
6
Exercise Prices	$ 6
Number of Warrants	2,864,457
Weighted Average Remaining Contractual Life (years)	4 years 7 months 13 days
Number Exercisable	2,864,457

DERIVATIVE FINANCIAL INSTRUME53

DERIVATIVE FINANCIAL INSTRUMENTS (Detail Textuals) - Dec. 31, 2013 - Warrant - USD ($)	Total
Derivative [Line Items]
Recorded loss on change in estimated fair value of warrants	$ 10,099,926
Derivative
Derivative [Line Items]
Total intrinsic value of derivative warrants outstanding and exercisable	$ 9,384,950
Closing stock price of stock options outstanding and exercisable	$ 7

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Dec. 31, 2013		Dec. 31, 2012
Asset:
Marketable securities, available-for-sale	$ 132,994	[1]
Liabilities:
Derivative liability related to warrants	25,037,346
Securities sold, not yet purchased	1,457,901
Settlement agreement	1,155,000
Quoted prices in active markets (Level 1)
Asset:
Marketable securities, available-for-sale	$ 132,994
Liabilities:
Derivative liability related to warrants
Securities sold, not yet purchased	$ 1,457,901
Settlement agreement	$ 1,155,000
Significant other observable inputs (Level 2)
Asset:
Marketable securities, available-for-sale
Liabilities:
Derivative liability related to warrants
Securities sold, not yet purchased
Settlement agreement
Significant unobservable inputs (Level 3)
Asset:
Marketable securities, available-for-sale
Liabilities:
Derivative liability related to warrants	$ 25,037,346
Securities sold, not yet purchased
Settlement agreement
[1]	(As Restated)

FAIR VALUE MEASUREMENTS (Deta55

FAIR VALUE MEASUREMENTS (Details 1) - Dec. 31, 2013 - USD ($)		Total	Total
Changes In Estimated Fair Value [Roll Forward]
Balance at January 1, 2013
Issuance of common stock warrants:
February 14, 2013		$ 5,407,372
August 14, 2013		328,561
August 15, 2013		9,201,487
Total value upon issuance		14,937,420
Change in fair value of common stock warrant liability	[1]	(10,099,926)	$ (10,099,926)
Balance at December 31, 2013		$ 25,037,346	$ 25,037,346
[1]	(As Restated)

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details)		Dec. 31, 2013USD ($)
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets	[1]	$ 10,560,355
Syntocinon License
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets		5,000,000
Carbetocin Assets
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets		$ 5,560,355
[1]	(As Restated)

INTANGIBLE ASSETS (Details 1)

INTANGIBLE ASSETS (Details 1) - USD ($)		Dec. 31, 2013		Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		$ 2,349,775		$ 2,318,093
Accumulated Amortization		(323,980)		(121,383)
Net Book Value		2,025,795	[1]	2,196,710
Lingand License Member
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		2,300,000		2,300,000
Accumulated Amortization		(323,980)		(121,383)
Net Book Value		1,976,020		2,178,617
Patent Costs
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	[2]	$ 49,775		$ 18,093
Accumulated Amortization	[2]
Net Book Value	[2]	$ 49,775		$ 18,093
[1]	(As Restated)
[2]	Patent costs will be amortized when a patent is procured and a life is assigned to the asset

INTANGIBLE ASSETS (Details 2)

INTANGIBLE ASSETS (Details 2) - USD ($)	Dec. 31, 2013		Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
2,014	$ 202,597
2,015	202,597
2,016	202,597
2,017	202,597
2,018	202,597
thereafter	1,012,810
Net Book Value	$ 2,025,795	[1]	$ 2,196,710
[1]	(As Restated)

INTANGIBLE ASSETS (Detail Textu

INTANGIBLE ASSETS (Detail Textuals) - Novartis Pharma AG and Novartis AG - Syntocinon License Agreement - USD ($)	Dec. 12, 2013	Dec. 31, 2013
Indefinite-lived Intangible Assets [Line Items]
Upfront fee of indefinite lived intangible assets	$ 5,000,000
Capitalized upfront fee of indefinite lived intangible asset	5,000,000
Accrued annual maintenance fee		$ 150,000
Regulatory Approval of Product for use in autism or schizophrenia indication from U.S. Food and Drug Administration
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	3,000,000
Enrollment of first patient in a clinical trial in NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	2,000,000
Enrollment of first patient in registration study in first indication for product in NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	2,000,000
Enrollment of first patient in registration study in second indication for product in NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	2,000,000
After receipt of positive results from registration study in first indication in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	5,000,000
After receipt of positive results from registration study in second indication in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	5,000,000
After filing NDA for first indication for any indication not set for the in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	10,000,000
After filing NDA for second indication for any indication not set for the in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	10,000,000
After Regulatory Approval of Product in first indication from FDA for any indication not set forth in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	15,000,000
After Regulatory Approval of Product in first indication from FDA for any indication not set forth in Initial NDA
Indefinite-lived Intangible Assets [Line Items]
Milestone payments	$ 15,000,000
Minimum
Indefinite-lived Intangible Assets [Line Items]
Royalty percentage	10.00%
Maximum
Indefinite-lived Intangible Assets [Line Items]
Royalty percentage	20.00%

INTANGIBLE ASSETS (Detail Tex60

INTANGIBLE ASSETS (Detail Textuals 1) - Kyalin - Carbetocin Technology Purchase - USD ($)	1 Months Ended
	Dec. 31, 2013	Dec. 23, 2013
Indefinite-lived Intangible Assets [Line Items]
Fixed minimum payments		$ 3,000,000
Basis for determining value of common stock issued or issuable		Share payments shall be issued based on the greater of (a) the average price per share quoted 30 trading days immediately preceding the date such shares first become issuable or (b) $7.0938 per share.
Value of common stock issued or issuable	$ 2,000,000
Maximum additional consideration payments		$ 2,000,000
Payments to acquire assets	$ 634,630	365,370
Recongized contingent consideration liability		2,634,630
Deferred purchase asset liability		2,634,630
Intangible assets basis stepped up		2,525,124
Completion Of First Phase II Study
Indefinite-lived Intangible Assets [Line Items]
Value of common stock issued or issuable		$ 800,000
Par value of common stock issued or issuable		$ 0.0001
Completion Of First Phase III Study
Indefinite-lived Intangible Assets [Line Items]
Value of common stock issued or issuable		$ 800,000
Par value of common stock issued or issuable		$ 0.0001
After receipt of FDA approval of an NDA
Indefinite-lived Intangible Assets [Line Items]
Value of common stock issued or issuable		$ 400,000
Par value of common stock issued or issuable		$ 0.0001
At closing
Indefinite-lived Intangible Assets [Line Items]
Cash paid		$ 500,000
First anniversary of Closing Date
Indefinite-lived Intangible Assets [Line Items]
Cash paid		500,000
Value of common stock issued or issuable		$ 1,000,000
Par value of common stock issued or issuable		$ 0.0001
Second anniversary of Closing Date
Indefinite-lived Intangible Assets [Line Items]
Value of common stock issued or issuable		$ 1,000,000
Par value of common stock issued or issuable		$ 0.0001

INTANGIBLE ASSETS (Detail Tex61

INTANGIBLE ASSETS (Detail Textuals 2) - USD ($)	Jan. 07, 2013	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Minimum
Finite-Lived Intangible Assets [Line Items]
Annual royalty percentage			15.00%
Maximum
Finite-Lived Intangible Assets [Line Items]
Annual royalty percentage			17.00%
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Remaining amortization period			9 years 6 months 14 days
Ligand License Agreement
Finite-Lived Intangible Assets [Line Items]
Nonrefundable payments	$ 2,550,000
First nonrefundable payment upon execution	$ 1,150,000
Second nonrefundable payment		$ 1,400,000
Fee payable to sublicensee		250,000
Cost of agreement			$ 2,300,000		$ 2,300,000
Extension fee		$ 250,000
Number of common stock issued or issuable	620,000
Value of common stock issued or issuable	$ 1,550,000
Amortization of Intangible Assets			202,597	$ 121,383	$ 323,890
Require to make substantial payments payable upon achievement of milestones			$ 106,900,000

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2013		Dec. 31, 2012
Payables and Accruals [Abstract]
Compensation related costs	$ 1,144,983		$ 1,022,716
Research and development	1,035,875		$ 679,800
Business development	300,000
License fee	150,000
Accounting and legal fees	$ 75,000		$ 563,380
Finder's fee			100,000
Other			11,250
Interest			$ 90,650
Other operating expenses	$ 1,428,837
Offering costs	746,739	[1]
Total	$ 4,881,434	[1]	$ 2,467,796
[1]	(As Restated)

SELLING, GENERAL, AND ADMINIS63

SELLING, GENERAL, AND ADMINISTRATIVE (Details) - USD ($)	Jan. 14, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
Selling General And Administrative
Professional fees (inclusive of share base compensation $1,485,393, $6,397,372, and $8,137,097)	$ 12,500	$ 5,600,455		$ 9,035,702	$ 15,249,423
Other		7,564,241		725,263	8,386,902
Compensation and related costs (inclusive of share base compensation $1,165,452, $16,012,850, and $18,903,269)		4,274,743		18,133,550	24,729,314
Technology license contingent fees		250,000		1,700,000	1,950,000
Total selling, general, and administrative expenses		$ 17,689,439	[1]	$ 29,594,515	$ 50,315,639	[1]
[1]	(As Restated)

SELLING, GENERAL, AND ADMINIS64

SELLING, GENERAL, AND ADMINISTRATIVE Parentheticals) (Details) - USD ($)	12 Months Ended		34 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Selling General And Administrative
Professional fees share base compensation	$ 1,485,393	$ 6,397,372	$ 8,137,097
Compensation and related costs share base compensation	$ 1,165,452	$ 16,012,850	$ 18,903,269

RESEARCH AND DEVELOPMENT (Detai

RESEARCH AND DEVELOPMENT (Details) - USD ($)	12 Months Ended			34 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013
External service provider costs:
Sparsentan	$ 2,443,273		$ 297,833	$ 2,619,723
RE024	1,548,957		$ 124,635	1,673,592
Weg license in process R&D (Note 14)	1,000,000			1,000,000
Syntocinon	250,540			250,540
RE034	230,279			230,279
General	159,080		$ 240,034	493,569
Other product candidates	117,771			376,710
Total external service provider costs:	5,749,900		$ 662,502	6,644,413
Internal personnel costs (inclusive of share base compensation $259,076, $0, and $259,076):	1,334,109			1,334,109
Total research and development	$ 7,084,009	[1]	$ 662,502	$ 7,978,522	[1]
[1]	(As Restated)

NOTES PAYABLE (Detail Textuals)

NOTES PAYABLE (Detail Textuals) - USD ($)	Mar. 05, 2012	Sep. 30, 2012	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013		Jun. 30, 2013	Feb. 01, 2012
Short-term Debt [Line Items]
Interest rate								5.00%
Interest expense, net			$ 46,344	[1]	$ 84,087	$ 130,356	[1]
Promissory notes payable
Short-term Debt [Line Items]
Secured promissory note issued to related party		$ 30,000
Interest rate		15.00%
Interest expense, net			$ 41,563		105,917	$ 147,480
Aggregate payment of debt instrument		$ 30,000
Secured promissory note
Short-term Debt [Line Items]
Secured promissory note issued to related party									$ 900,000
Interest rate									12.00%
Aggregate payment of debt instrument	$ 25,000
Accrued interest	9,764
Consecutive payment of notes payable	$ 15,236
Remaining principal balance of note					$ 884,764
[1]	(As Restated)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended		34 Months Ended
	Aug. 31, 2012	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	[1]
Related Party Transaction [Line Items]
Payments made on behalf of affiliate	$ 137,547			$ 137,547	$ 137,547
Paid legal fees on behalf affiliate			$ 150,000
Write off bad debt expense				$ 563,380
Liabilitie settled to series of agreements		$ 2,284,511
Shares issued on behalf of related party	$ 80,800		80,800
Cash consideration			2,203,711
Issuance for common stock for investment		47,128
Amount paid at the time of filing		$ 2,284,511
Principal amount on agreement		$ 2,284,511
Interest rate		5.00%
Common stock
Related Party Transaction [Line Items]
Shares issued on behalf of related party			$ 1
Shares issued on behalf of related party (in shares)			11,000
[1]	(As Restated)

RELATED PARTY TRANSACTIONS (D68

RELATED PARTY TRANSACTIONS (Detail Textuals 1) - USD ($)	Aug. 15, 2013	Aug. 14, 2013	Jan. 31, 2013	Dec. 31, 2013	Aug. 31, 2013
Related Party Transaction [Line Items]
Number of shares issued in transaction	73,710
Sale price per share					$ 5
Proceeds from Issuance of Private Placement				$ 30,900,000
Number of common stock called by warrants	98,756
Private Placement Offerings
Related Party Transaction [Line Items]
Number of shares issued in transaction	5,531,401	73,710
Sale price per share	$ 4.50	$ 4.50
Proceeds from Issuance of Private Placement	$ 24,891,303	$ 328,561	$ 103,425
Number of common stock called by warrants	2,765,701	98,756
Exercise price of warrant	$ 6
Number of common stock purchase by management	10,522
Number of common stock called by warrants in privet placement	5,261

RELATED PARTY TRANSACTIONS (D69

RELATED PARTY TRANSACTIONS (Detail Textuals 2)

Jan. 14, 2014USD ($)

Jan. 09, 2014shares

Mar. 31, 2014shares

Dec. 31, 2013USD ($)Agreementshares

Sep. 30, 2013shares

Sep. 20, 2013shares

Aug. 29, 2013USD ($)

Dec. 31, 2013USD ($)Agreementshares

Dec. 31, 2013USD ($)Agreement

Dec. 31, 2012USD ($)

Dec. 31, 2013USD ($)Agreement

Related Party Transaction [Line Items]

Cash payments

$ 300,000

$ 13,200

[1]

$ 33,300

$ 46,500

[1]

Consultant fees per month

$ 12,500

5,600,455

$ 9,035,702

$ 15,249,423

License fee

150,000

Subsequent Event

Related Party Transaction [Line Items]

Number of common stock issued (in shares) | shares

4,705,882

Settlement Agreement

Related Party Transaction [Line Items]

Consultant fees per month

135,000

Aggregate issuance date fair value of the shares issued/issuable

$ 2,708,375

Share base payment liability to current fair value

$ 173,625

License fee

$ 165,000

Settlement Agreement | Mr. Shkreli

Related Party Transaction [Line Items]

Number of settlement agreement | Agreement

2

2

2

2

Number of common stock issued (in shares) | shares

346,500

Cash payments

$ 200,000

First agreement

Related Party Transaction [Line Items]

Number of common stock issued (in shares) | shares

50,000

50,000

331,500

Number of common stock issued upon execution of agreement | shares

131,500

First agreement | Subsequent Event

Related Party Transaction [Line Items]

Number of common stock issued (in shares) | shares

50,000

Second Agreement

Related Party Transaction [Line Items]

Number of common stock issued (in shares) | shares

15,000

Consultant fees per month

$ 50,000

[1]

(As Restated)

COMMITMENTS AND CONTINGENCIES70

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2013USD ($)
Research and Development and other Charitable Donations
2,014	$ 4,560,092
2,015	$ 2,950,294
2,016
2,017
2,018
2019 and thereafter
Total	$ 7,510,386
Consultant
2,014	$ 831,660
2,015
2,016
2,017
2,018
2019 and thereafter
Total	$ 831,660
Operating Leases
2,014	777,538
2,015	811,149
2,016	724,292
2,017	$ 12,850
2,018
2019 and thereafter
Total	$ 2,325,829

COMMITMENTS AND CONTINGENCIES71

COMMITMENTS AND CONTINGENCIES (Detail Textuals) - Leases and Sublease Agreements	Dec. 01, 2013USD ($)ft²	Oct. 08, 2013USD ($)ft²	Oct. 01, 2013USD ($)ft²	Oct. 31, 2012USD ($)ft²
Commitment And Contingency [Line Items]
Area of office space				4,216
Percentage of rent and related escalations paid				50.00%
Percentage of utilities incurred by the sublessor				50.00%
MASSACHUSETTS
Commitment And Contingency [Line Items]
Area of office space			4,232
Anual base rent | $			$ 216,000
CALIFORNIA
Commitment And Contingency [Line Items]
Area of office space	2,500
Anual base rent | $	$ 70,500
NEW YORK
Commitment And Contingency [Line Items]
Area of office space		4,000
Anual base rent | $		$ 225,000		$ 275,000

COMMITMENTS AND CONTINGENCIES72

COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) - USD ($)	Jan. 14, 2014	Dec. 01, 2013	Nov. 08, 2013	Nov. 01, 2011	Aug. 15, 2011	Jun. 29, 2014	Mar. 29, 2014	Oct. 26, 2013	Feb. 15, 2013	Sep. 30, 2012	Aug. 25, 2011	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Commitment And Contingency [Line Items]
Professional fees	$ 12,500												$ 5,600,455	$ 9,035,702	$ 15,249,423
Value of shares issued										$ 4,400,000
Number of shares vested												491,075	275,793	2,241,952
Consultant Agreement | Consultant | Agreement Date August 15, 2011
Commitment And Contingency [Line Items]
Initial term of agreement					1 year
Professional fees					$ 37,500								$ 153,000	$ 150,000	378,500
Amount of fee payable													0	155,000	0
Number of shares issued					25,000
Value of shares issued					$ 100,000
Description of shares vested					vests over twelve (12) quarters so long as the agreement remains in effect
Consultant Agreement | Consultant | Agreement Date November 1, 2011
Commitment And Contingency [Line Items]
Professional fees													195,000	210,000	445,000
Number of shares issued				120,000
Value of shares issued				$ 480,000
Description of shares vested				vest in over twelve (12) calendar quarters commencing December 31, 2011
Consultant Agreement | Consultant | Agreement Date October 26, 2013
Commitment And Contingency [Line Items]
Professional fees								$ 26,666					$ 780,000		780,000
Number of shares issued						50,000	50,000	200,000					100,000
Consultant Agreement | Consultant | Agreement Date December 1, 2013
Commitment And Contingency [Line Items]
Professional fees		$ 26,666											$ 780,000		780,000
Number of shares issued		200,000				50,000	50,000						100,000
Consultant Agreement | Consultant | Agreement Date August 25, 2011
Commitment And Contingency [Line Items]
Initial term of agreement											1 year
Professional fees											$ 50,000		$ 225,000	200,000	525,000
Number of shares issued											145,000
Value of shares issued											$ 580,000
Description of shares vested											vested over twelve (12) quarters so long as the agreements remained in effect
Number of shares vested													34,575
Consultant Agreement | Consultant | Agreement Date November 1, 2011
Commitment And Contingency [Line Items]
Initial term of agreement				1 year
Professional fees				$ 50,000									$ 225,000	200,000	525,000
Number of shares issued				145,000
Value of shares issued				$ 580,000
Description of shares vested				vested over twelve (12) quarters so long as the agreements remained in effect
Number of shares vested													34,575
Consultant Agreement | Consultant | Agreement Date February 15, 2013
Commitment And Contingency [Line Items]
Professional fees													$ 52,500	$ 0	$ 52,500
Number of shares issued									12,500
Value of shares issued									$ 52,500
Consultant Agreement | Consultant | Agreement Date November 8, 2013
Commitment And Contingency [Line Items]
Professional fees			$ 15,000

COMMITMENTS AND CONTINGENCIES73

COMMITMENTS AND CONTINGENCIES (Detail Textuals 2) - Subsequent Event Type [Domain]

Jan. 14, 2014USD ($)

Dec. 12, 2013USD ($)

Dec. 11, 2013USD ($)Contribution

Dec. 03, 2013USD ($)

Dec. 03, 2013CAD

Oct. 01, 2013USD ($)Installment

Jul. 12, 2013USD ($)

Jul. 12, 2013CAD

Jul. 01, 2012USD ($)

Oct. 31, 2013USD ($)

Oct. 22, 2013USD ($)

Dec. 31, 2013USD ($)

Dec. 31, 2012USD ($)

Dec. 31, 2013USD ($)

Oct. 02, 2013USD ($)

Commitment And Contingency [Line Items]

Amount of fee payable

$ 75,000

$ 563,380

$ 75,000

Professional fees

$ 12,500

5,600,455

9,035,702

15,249,423

SickKids

Commitment And Contingency [Line Items]

Sponsor fees

$ 234,490

CAD 250,000

$ 721,470

CAD 750,000

Sponsorship period

3 years

3 years

Professional fees

113,327

Total obligation

$ 467,425

CAD 500,000

Yearly installment

$ 233,713

CAD 250,000

University of Michigan

Commitment And Contingency [Line Items]

Payment for fees

$ 250,000

Maximum funding of charitable contribution

$ 2,000,000

Period specified for charitable contribution

2 years

UCSD

Commitment And Contingency [Line Items]

Payment for fees

0

Period specified for charitable contribution

2 years

1 year

Payment for unrestricted charitable contribution

$ 530,000

Accrued expenses

40,082

40,082

Research program fees

$ 1,540,000

Research program fees for per quarter

$ 192,500

Period for written notice

60 days

Number of contribution | Contribution

3

Sponsored Research Agreement | St. Jude

Commitment And Contingency [Line Items]

Payment for fees

$ 203,169

$ 195,169

Sponsor fees

$ 780,674

$ 203,169

$ 101,314

$ 101,855

$ 203,169

Number of installments | Installment

4

Term of agreement

2 years

Professional fees

$ 97,584

Weg License Agreement | For the first NDA acceptance for depression indication

Commitment And Contingency [Line Items]

Milestone payments

2,500,000

Weg License Agreement | After the first FDA approval for products for depression indication

Commitment And Contingency [Line Items]

Milestone payments

2,500,000

Weg License Agreement | For the first NDA acceptance of product not included in previously accepted NDA

Commitment And Contingency [Line Items]

Milestone payments

2,500,000

Weg License Agreement | For the first FDA approval for products not included in previous FDA approval

Commitment And Contingency [Line Items]

Milestone payments

2,500,000

Weg License Agreement | Dr. Weg

Commitment And Contingency [Line Items]

License maintenance and sublicensing fees

$ 1,000,000

Weg License Agreement | FDA | Minimum

Commitment And Contingency [Line Items]

Royalty percentage

3.00%

Weg License Agreement | FDA | Maximum

Commitment And Contingency [Line Items]

Royalty percentage

8.00%

Weg License Agreement | U.S. Patent and Trademark Office | After a patent covering products

Commitment And Contingency [Line Items]

Milestone payments

$ 1,000,000

COMMITMENTS AND CONTINGENCIES74

COMMITMENTS AND CONTINGENCIES (Detail Textuals 3) - USD ($)	Dec. 16, 2013	Dec. 06, 2013	Sep. 18, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2013	Aug. 15, 2013	Feb. 28, 2013	Jan. 31, 2013
Commitment And Contingency [Line Items]
Number of options to purchase shares of restricted common stock				2,139,300	335,000	953,683
Issuance of common stock, per share amount (in dollars per share)							$ 4.50	$ 4.50	$ 3	$ 3
Transcept Pharmaceuticals, Inc.
Commitment And Contingency [Line Items]
Issuance of common stock, per share amount (in dollars per share)			$ 4
Payments to acquire equity method investments			$ 3,000,000
Equity method investment, ownership percentage			4.96%
Gain on the sale of Transcept shares					$ 235,839
Non-employee directors
Commitment And Contingency [Line Items]
Number of options to purchase shares of restricted common stock					51,000
Compensation to non-employee directors		$ 100,000
Threshold limit of cash in compensation		$ 25,000
Compensation description		Board of directors established a compensation policy for the Company's non-employee directors pursuant to which each non-employee director shall receive $100,000 annually, which amount shall be comprised of not more than $25,000 in cash, with the remainder paid in the form of options to purchase shares of the Company's common stock. Each non-employee director may, at his discretion, determine to receive less than $25,000 annually in the form of cash, in which case such amount will be paid to such director in the form of options to purchase additional shares of the Company's common stock.
Number of options exercisable		51,000
Options exercisable, weighted-average exercise price		$ 8.70
Options vesting period (in years)		10 years
Employment Agreement | Mr. Shkreli
Commitment And Contingency [Line Items]
Base salary	$ 300,000
Term of agreement	3 years
Employment agreement, description	The Shkreli Employment Agreement contemplates that Mr. Shkreli's employment will be for a three-year term and may be automatically extended for successive three-year periods unless (i) Mr. Shkreli gives notice of non-extension to the Company no later than one hundred eighty (180) days prior to the expiration of the Agreement or (ii) Mr. Shkreli is terminated.
Employment Agreement | Mr. Shkreli | Restricted common stock
Commitment And Contingency [Line Items]
Number of options to purchase shares of restricted common stock	1,080,000
Options vesting period (in years)	3 years

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - USD ($) $ / shares in Units, $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Number of share granted during the period	2,139,300	335,000	953,683
Cancelled during the period, Options	45,835	58,333	46,353
Granted during the period, Weighted-Average Exercise Price		$ 6.03
Remaining Contractual Term, Outstanding at December 31, 2013 (in years)		2 years 2 months 8 days
Stock option
Outstanding
Number of share granted during the period		1,721,000
Cancelled during the period, Options
Exercised during the period, Options
Shares Outstanding, Ending		1,721,000
Outstanding, Beginning
Granted during the period, Weighted-Average Exercise Price		$ 7.66
Cancelled during the period, Weighted-Average Exercise Price
Exercised during the period, Weighted-Average Exercise Price
Outstanding, Ending		$ 7.66
Exercisable, Weighted-Average Exercise Price		$ 7.85
Remaining Contractual Term, Outstanding at December 31, 2013 (in years)		9 years 10 months 21 days
Remaining Contractual Term, Exercisable at December 31, 2013 (in years)		9 years 10 months 10 days
Aggregate Intrinsic Value, Outstanding at December 31, 2013		$ 172,000
Aggregate Intrinsic Value, Exercisable at December 31, 2013		$ 14,333

STOCKHOLDERS' DEFICIT (Detail T

STOCKHOLDERS' DEFICIT (Detail Textuals) - USD ($)		Aug. 15, 2013	Aug. 14, 2013	Jan. 04, 2013	Feb. 14, 2013	Jan. 31, 2013	May. 18, 2012	Jan. 25, 2012	Mar. 31, 2011	Mar. 30, 2011	Dec. 11, 2012	Jun. 30, 2011	Sep. 25, 2012	May. 14, 2012	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2013		Aug. 31, 2013	Feb. 28, 2013	Dec. 31, 2012	Sep. 20, 2012
Stockholders Deficit [Line Items]
Common stock shares authorized																100,000,000	[1]	100,000,000	[1]			100,000,000
Common stock par value per share (in dollars per share)																$ 0.0001	[1]	$ 0.0001	[1]			$ 0.0001
Common stock voting rights																Vote on a 1 share/1 vote basis
Preferred stock shares authorized																20,000,000	[1]	20,000,000	[1]			20,000,000
Preferred stock par value per share																$ 0.001	[1]	$ 0.001	[1]			$ 0.001
Value of common stock shares issued
Price per share		$ 4.50				$ 3														$ 4.50	$ 3
Proceeds from private placement																$ 30,900,000
Fees in connection with private placement	[1]															746,739		$ 746,739
Number of common stock called by warrants		98,756
Derivative liability related to warrants																$ 25,037,346		$ 25,037,346
Percentage of liquidated damages equal to purchase price		2.00%
Interest rate per annum		18.00%
Registration Rights Agreement
Stockholders Deficit [Line Items]
Percentage of liquidated damages equal to purchase price					2.00%
Interest rate per annum					18.00%
Registration payment arrangement liability					$ 360,000
Income recognized upon waiver of liquidated damages					$ 360,000
Maximum | Registration Rights Agreement
Stockholders Deficit [Line Items]
Percentage of liquidated damages equal to purchase price		10.00%			10.00%
Common stock
Stockholders Deficit [Line Items]
Number of common stock issued (in shares)															1,608,300
Value of common stock shares issued															$ 161
Common stock | Founder
Stockholders Deficit [Line Items]
Number of common stock issued (in shares)										1,608,300
Value of common stock shares issued										$ 25,000
Common stock | Member
Stockholders Deficit [Line Items]
Number of common stock issued (in shares)									50,000
Value of common stock shares issued									$ 100
Private Placement Offerings
Stockholders Deficit [Line Items]
Proceeds from private placement		$ 24,891,303	$ 328,561			$ 103,425
Number of common stock called by warrants		2,765,701	98,756
Exercise price of warrant		$ 6
Private Placement Offerings | Common stock
Stockholders Deficit [Line Items]
Common stock voting rights									One (1) vote per each unit
Number of common stock issued (in shares)		5,531,401			3,045,929	272,221			500,000
Value of common stock shares issued		$ 24,891,303			$ 9,137,787	$ 816,664			$ 2,000,000
Price per share		$ 4.50			$ 3	$ 3			$ 4			$ 4
Proceeds from private placement												$ 725,000
Fees in connection with private placement												$ 66,061
Number of common stock called by warrants		2,765,701			1,597,969
Exercise price of warrant		$ 6			$ 3.60
Derivative liability related to warrants		$ 9,201,487			$ 4,505,605
Private Placement Offerings | Common stock | Roth Capital Partners
Stockholders Deficit [Line Items]
Price per share				$ 3.60
Fees in connection with private placement				$ 624,033
Number of common stock called by warrants				319,823
Derivative liability related to warrants				$ 901,767
Class "A" Preferred shares
Stockholders Deficit [Line Items]
Preferred stock shares authorized																1,000		1,000
Preferred stock par value per share																$ 0.001		$ 0.001
Class "A" Preferred shares | Common stock
Stockholders Deficit [Line Items]
Conversion of stock shares issued												253,750
Class "A" Preferred shares | Private Placement Offerings
Stockholders Deficit [Line Items]
Number of common stock issued (in shares)							875,000	875,000
Price per share							$ 11.43	$ 5.71			$ 3.57		$ 3.57	$ 5.71									$ 3.57
Proceeds from private placement											$ 710,501		$ 970,800	$ 1,868,354
Fees in connection with private placement													$ 12,275	$ 61,677
Conversion of stock shares issued											198,940		271,824	326,963
[1]	(As Restated)

STOCKHOLDERS' DEFICIT (Detail77

STOCKHOLDERS' DEFICIT (Detail Textuals 1) - Entity [Domain] - USD ($)		Aug. 15, 2013	Aug. 14, 2013	Feb. 03, 2012	Aug. 31, 2013	Feb. 14, 2013	Jan. 31, 2013	Sep. 30, 2012	May. 18, 2012	Apr. 30, 2012	Jan. 25, 2012	Dec. 31, 2012	Dec. 11, 2012	Sep. 25, 2012	May. 14, 2012	Dec. 31, 2013	Sep. 20, 2012	Dec. 31, 2013	Feb. 28, 2013
Stockholders Deficit [Line Items]
Aggregate fee paid to investors		$ 2,495,256
Number of shares issued in transaction		73,710
Fair value of common stock		$ 331,695
Price per share		$ 4.50			$ 4.50		$ 3												$ 3
Common stock value per share					$ 5
Repayment of common stock proceeds		$ 1,835,000
Number of common stock called by warrants		98,756
Fair value of warrant		$ 328,561
Common stock purchase option price		$ 4.50
Portion of fee settled in cash		$ 946,196
Additional repayment to investor		$ 103,425
Number of shares issued for additional repayment		197,512			20,685
Waiver of original registration payment obligation		$ 360,000
Reduction of proceeds received in financing transaction		$ 2,238,681
Percentage of liquidated damages equal to purchase price		2.00%
Interest rate per annum		18.00%
Proceeds from private placement																$ 30,900,000
Fees in connection with private placement	[1]															$ 746,739		$ 746,739
Stock issued for services, value								$ 4,400,000
Notes receivable from related parties				$ 200,000
Interest rate of notes receivable				12.00%
Value of notes receiable as reduction of stockholders equity												$ 372,900
Registration Rights Agreement
Stockholders Deficit [Line Items]
Percentage of liquidated damages equal to purchase price						2.00%
Interest rate per annum						18.00%
Private Placement Offerings
Stockholders Deficit [Line Items]
Aggregate fee paid to investors			$ 2,495,256
Number of shares issued in transaction		5,531,401	73,710
Common stock value per share		$ 4.50	$ 4.50
Number of common stock called by warrants		2,765,701	98,756
Proceeds from private placement		$ 24,891,303	$ 328,561				$ 103,425
Class "A" Preferred shares | Private Placement Offerings
Stockholders Deficit [Line Items]
Price per share									$ 11.43		$ 5.71		$ 3.57	$ 3.57	$ 5.71		$ 3.57
Selling price of preferred shares before amendment																	$ 11.43
Number of common stock issued (in shares)									875,000		875,000
Proceeds from private placement													$ 710,501	$ 970,800	$ 1,868,354
Fees in connection with private placement														$ 12,275	$ 61,677
Conversion of stock shares issued													198,940	271,824	326,963
Stock issued during period shares to related party														185,024	128,163
Stock issued during period value to related party														$ 660,800	$ 732,353
Maximum | Registration Rights Agreement
Stockholders Deficit [Line Items]
Percentage of liquidated damages equal to purchase price		10.00%				10.00%
Founding Stockholder
Stockholders Deficit [Line Items]
Stock issued for services, shares												275,000
Stock issued for services, value												$ 1,375,000
Founding Stockholder | Consultant
Stockholders Deficit [Line Items]
Stock issued for services, shares										300,000
Founder | Former Chief Executive Officer
Stockholders Deficit [Line Items]
Stock issued for services, shares								250,000
[1]	(As Restated)

STOCKHOLDERS' DEFICIT (Detail78

STOCKHOLDERS' DEFICIT (Detail Textuals 2)	Dec. 16, 2013USD ($)$ / sharesshares	Dec. 09, 2013USD ($)Employee$ / sharesshares	Dec. 06, 2013USD ($)Director$ / sharesshares	Sep. 09, 2013USD ($)Employee$ / sharesshares	Aug. 13, 2013USD ($)$ / sharesshares	May. 13, 2013USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2011shares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012shares
Stockholders Deficit [Line Items]
Number of share granted during the period | shares								2,139,300	335,000	953,683
Exercise price | $ / shares							$ 7		$ 7
Weighted average grant date fair value of option granted | $ / shares									$ 6.03
Unrecognized compensation cost							$ 1,105,967		$ 1,105,967
Weighted average remaining vesting period Unrecognized compensation cost									2 years 8 months 12 days
Number of stock repurchased | shares									130,790
Value of stock repurchased									$ (957,272)
Consultant | Options
Stockholders Deficit [Line Items]
Number of share granted during the period | shares							359,000
Compensation expense related to options							$ 2,485,875
Weighted average grant date fair value of option granted | $ / shares							$ 6.92
Employment Agreement | Options
Stockholders Deficit [Line Items]
Number of share granted during the period | shares		330,000	51,000	90,000	50,000
Estimated fair value of options issued		$ 2,236,848	$ 350,085	$ 448,354	$ 193,765
Number of employees | Employee		6		2
Number of board of directors | Director			4
Options vesting period (in years)		3 years		3 years	3 years
Options valuation method		Black-Scholes options pricing model	Black-Scholes options pricing model	Black- Scholes options pricing model	Black- Scholes options pricing model
Risk free interest rate		1.51%	1.51%	1.71%	1.49%
Expected term (in years)		5 years 9 months 22 days	5 years 9 months 22 days	5 years 9 months 22 days	5 years 9 months 22 days
Expected volatility		101.66%	101.66%	104.78%	98.56%
Exercise price | $ / shares		$ 8.10	$ 8.70	$ 6.20	$ 5
Compensation expense related to options		$ 50,019	$ 350,085	$ 46,268	$ 24,774
Employment Agreement | Horacio Plotkin, M.D. | Options
Stockholders Deficit [Line Items]
Number of share granted during the period | shares						120,000
Estimated fair value of options issued						$ 804,732
Options vesting period (in years)						3 years
Options valuation method						Black-Scholes options pricing model
Risk free interest rate						0.83%
Expected term (in years)						5 years 9 months 22 days
Expected volatility						98.56%
Exercise price | $ / shares						$ 8.70
Compensation expense related to options						$ 170,500
Employment Agreement | Martin Shkreli | Options
Stockholders Deficit [Line Items]
Number of share granted during the period | shares	1,080,000
Estimated fair value of options issued	$ 6,350,400
Options vesting period (in years)	3 years
Options valuation method	Black-Scholes options pricing model
Risk free interest rate	1.55%
Expected term (in years)	5 years 9 months 22 days
Expected volatility	101.66%
Exercise price | $ / shares	$ 7.45
Compensation expense related to options	$ 529,200

INCENTIVE SHARES (Details)

INCENTIVE SHARES (Details) - $ / shares	10 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Number of shares
Unvested, beginning balance		267,768	1,602,390
Granted	2,139,300	335,000	953,683
Vested	(491,075)	(275,793)	(2,241,952)
Forfeited	(45,835)	(58,333)	(46,353)
Unvested, ending balance	1,602,390	268,642	267,768
Weighted Average Fair Value
Unvested, beginning balance		$ 3.20	$ 4
Granted	$ 4	6.24	12.89
Vested	$ 4	5.44	$ 7.34
Forfeited		4
Unvested, ending balance	$ 4	$ 6.44	$ 3.20
Employee
Number of shares
Unvested, beginning balance		52,772	1,281,225
Granted	1,758,300	135,000	866,180
Vested	(431,240)	(36,724)	(2,048,280)
Forfeited	(45,835)	(20,833)	(46,353)
Unvested, ending balance	1,281,225	130,215	52,772
Non Employee
Number of shares
Unvested, beginning balance		214,996	321,165
Granted	381,000	200,000	87,503
Vested	(59,835)	(239,069)	(193,672)
Forfeited		(37,500)
Unvested, ending balance	321,165	138,427	214,996

INCENTIVE SHARES (Detail Textua

INCENTIVE SHARES (Detail Textuals)	Dec. 11, 2012shares	Jul. 07, 2012USD ($)$ / sharesshares	Mar. 07, 2012USD ($)$ / sharesshares	Jan. 30, 2012USD ($)$ / sharesshares	Mar. 31, 2011USD ($)$ / sharesshares	Nov. 30, 2011USD ($)Consultant$ / sharesshares	Sep. 11, 2012shares	Dec. 31, 2011shares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2012USD ($)shares	Dec. 31, 2013USD ($)$ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period | shares								2,139,300	335,000	953,683
Closing stock price | $ / shares									$ 7		$ 7
Number of shares vested | shares								491,075	275,793	2,241,952
Stock-based compensation									$ 986,575	$ 22,410,222	$ 27,300,000
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period | shares				826,600
Aggregate fair value of shares				$ 9,919,200
Closing stock price | $ / shares				$ 12
Number of shares vested | shares	573,015			28,185	938,175		938,175
Stock-based compensation				$ 7,214,400	$ 3,216,600
Share-based payment award, vesting period				3 years	3 years
Executive and non-executive employees, and consultants
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period | shares					1,849,300
Aggregate fair value of shares					$ 7,397,200
Closing stock price | $ / shares					$ 4
Consultants
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period | shares			83,333			290,000
Aggregate fair value of shares			$ 2,000,000			$ 1,160,000
Closing stock price | $ / shares		$ 8.6	$ 24			$ 4
Number of consultants | Consultant						2
Share-based payment award, vesting period			2 years			3 years
Percentage of immediately vested shares			50.00%
Employees
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period | shares		43,750
Aggregate fair value of shares		$ 375,000
Closing stock price | $ / shares		$ 8.6
Stock-based compensation									$ 253,682
Percentage of immediately vested shares		3.00%

INCENTIVE SHARES (Detail Text81

INCENTIVE SHARES (Detail Textuals 1) - USD ($)	Jul. 07, 2012	Jul. 31, 2013	May. 20, 2013	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period				2,139,300	335,000	953,683
Stock-based compensation					$ 986,575	$ 22,410,222	$ 27,300,000
Unrecognized compensation cost					$ 1,105,967		$ 1,105,967
Weighted average period					2 years 2 months 8 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based payment award, vesting period					3 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based payment award, vesting period					2 years
Employees
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period	43,750
Aggregate fair value of shares	$ 375,000
Stock-based compensation					$ 253,682
Non Employees
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation					$ 732,893
Restricted Stock | Marc L. Panoff | Panoff employment agreement
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period			120,000
Aggregate fair value of shares			$ 768,000
Share-based payment award, vesting period			3 years
Restricted Stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of share granted during the period		15,000
Aggregate fair value of shares		$ 75,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended			34 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013	[1]
Current
Federal
State
Current, Total
Deferred
Federal	$ (6,293,000)		$ (1,173,000)
State	(3,435,000)		(733,000)
Deferred, Total	(9,728,000)		(1,906,000)
Total	(9,728,000)		(1,906,000)
Change in valuation allowance	9,804,000		$ 1,906,000
Income tax (benefit)	$ 75,775	[1]		$ 75,775
[1]	(As Restated)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Statutory rate - federal	(35.00%)	(35.00%)
State taxes, net of federal benefit	(6.70%)	(1.81%)
Change in FV of derivative liability (warrants)	10.46%	0.00%
Stock Based Compensation related to profits interest	2.30%	9.52%
Other	0.17%	1.62%
Partnership losses preceding conversion	0.00%	19.39%
Change in valuation allowance	29.00%	6.28%
Income tax provision (benefit)	0.23%	0.00%

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Net operating loss and capital loss carryforward	$ 11,832	$ 2,748
Intangible assets	(2,999)	(466)
Other	610	(376)
Valuation allowance	(12,044)	$ (1,906)
Total Deferred tax liability	$ (2,601)

INCOME TAXES (Detail Textuals)

INCOME TAXES (Detail Textuals) - USD ($)	12 Months Ended	18 Months Ended
	Dec. 31, 2013	Sep. 20, 2012	Dec. 23, 2013
Operating Loss Carryforwards [Line Items]
Deferred tax liability and income tax expense recorded related to technology license		$ 1,079,000
Provision for deferred income tax	$ 76,000
Kyalin | Carbetocin Technology Purchase
Operating Loss Carryforwards [Line Items]
Intangible assets basis stepped up			$ 2,525,124
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	25,300,000
State and local
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 25,300,000

SUBSEQUENT EVENTS (Detail Textu

SUBSEQUENT EVENTS (Detail Textuals)

Jan. 09, 2014USD ($)$ / sharesshares

Dec. 01, 2013USD ($)

Mar. 26, 2014USD ($)Installment

Feb. 28, 2014USD ($)Square_Feet

Dec. 31, 2013USD ($)shares

Dec. 31, 2012USD ($)

Dec. 31, 2013USD ($)

Aug. 31, 2013$ / shares

Aug. 15, 2013$ / shares

Feb. 28, 2013$ / shares

Jan. 31, 2013$ / shares

Sep. 30, 2012USD ($)

Subsequent Event [Line Items]

Price per share | $ / shares

$ 4.50

$ 4.50

$ 3

$ 3

Realized a gain of sale of Transcept shares

$ 30,936,748

[1]

$ 3,475,703

$ 35,175,123

[1]

Purchase of marketable securities

[1]

$ 4,124,482

$ 4,124,482

Number of stock repurchased | shares

130,790

Value of stock repurchased

$ (957,272)

Warrant

Subsequent Event [Line Items]

Warrants exercised | shares

798,391

Proceeds exercise of warrants

$ 3,830,316

Promissory notes payable

Subsequent Event [Line Items]

Principal amount of promissory note

$ 30,000

Leases and Sublease Agreements | Carlsbad, CA

Subsequent Event [Line Items]

Anual base rent

$ 70,500

Subsequent Event

Subsequent Event [Line Items]

Number of common stock issued (in shares) | shares

4,705,882

Price per share | $ / shares

$ 8.50

Realized a gain of sale of Transcept shares

$ 37,399,997

Payments to acquire businesses

$ 29,500,000

Purchase of marketable securities

1,019,456

Realized a gain on securities sold, not yet purchased

$ 45,885

Number of stock repurchased | shares

248,801

Value of stock repurchased

$ 2,257,336

Subsequent Event | Retrophin Therapeutics International LLC

Subsequent Event [Line Items]

Payments to acquire businesses

$ 3,200,000

Subsequent Event | Manchester Pharmaceuticals, LLC

Subsequent Event [Line Items]

Acquired percentage

100.00%

Subsequent Event | Manchester Pharmaceuticals, LLC | Promissory notes payable

Subsequent Event [Line Items]

Principal amount of promissory note

$ 33,000,000

Frequency of periodic payments for notes payable

three equal installments

Number of installments | Installment

3

Consecutive payment of notes payable

$ 11,000,000

Subsequent Event | Leases and Sublease Agreements | Carlsbad, CA

Subsequent Event [Line Items]

Office space | Square_Feet

3,800

Anual base rent

$ 110,000

[1]

(As Restated)

SUBSEQUENT EVENTS (Detail Tex87

SUBSEQUENT EVENTS (Detail Textuals 1) - USD ($)

Jan. 01, 2015

Oct. 01, 2014

Jul. 01, 2014

Apr. 01, 2014

Jan. 14, 2014

Jan. 09, 2014

Dec. 30, 2014

Sep. 29, 2014

Jun. 29, 2014

Mar. 31, 2014

Feb. 24, 2014

Feb. 14, 2014

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Subsequent Event [Line Items]

Granted

2,139,300

335,000

953,683

Consultant fees per month

$ 12,500

$ 5,600,455

$ 9,035,702

$ 15,249,423

Securities sold, not yet purchased

1,457,901

[1]

1,457,901

[1]

Consulting Agreements

Subsequent Event [Line Items]

Consultant fees per month

135,000

Subsequent Event

Subsequent Event [Line Items]

Issuance of common shares (in shares)

4,705,882

Cash Bonus Pool

$ 1,100,000

Securities sold, not yet purchased

1,218,800

1,218,800

Unrealized loss related to securities sold, not yet purchased

$ 498,146

$ 498,146

Subsequent Event | Three officers

Subsequent Event [Line Items]

Issuance of common shares (in shares)

400,000

Subsequent Event | Four officers and other employees

Subsequent Event [Line Items]

Granted

1,210,000

Subsequent Event | Consulting Agreements

Subsequent Event [Line Items]

Granted

14,000

66,000

Issuance of common shares (in shares)

3,500

3,500

3,500

3,500

16,500

16,500

16,500

16,500

Consultant fees per month

$ 12,500

$ 200,000

Expiration date of agreement

Jan. 13, 2015

Dec. 31, 2014

Number of shares issued

200,000

[1]

(As Restated)

Uncategorized Items - rtrx-2013

Label	Element	Value
Cash and Cash Equivalents, at Carrying Value	us-gaap_CashAndCashEquivalentsAtCarryingValue
Additional Paid-In Capital
Shares, Issued	us-gaap_SharesIssued
Stockholder's deficit	us-gaap_StockholdersEquity
Common Stock [Member]
Shares, Issued	us-gaap_SharesIssued
Stockholder's deficit	us-gaap_StockholdersEquity
Accumulated Deficit
Shares, Issued	us-gaap_SharesIssued
Stockholder's deficit	us-gaap_StockholdersEquity
Receivables Due From Stockholder
Shares, Issued	us-gaap_SharesIssued
Stockholder's deficit	us-gaap_StockholdersEquity